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ABSTRACT 
Existing data suggest that NF-kappaB signaling is a key regulator of 
cancer-induced skeletal muscle wasting. However, identification of the 
components of this signaling pathway and of the NF-kappaB transcription factors 
that regulate wasting is far from complete. In muscles of C26 tumor-bearing 
mice, overexpression of dominant-negative (d.n.) IKKbeta and the lkappaBalpha-
super repressor blocked wasting by 69% and 41%, respectively. In contrast, 
overexpression of d.n. IKKalpha or d.n. NIK did not block C26-induced muscle 
wasting. Surprisingly, overexpression of d.n . ReiA (p65) or d.n. c-Rel did not 
significantly affect muscle wasting. Genome-wide mRNA expression arrays 
showed upregulation of many genes previously implicated in muscle atrophy. To 
test if these upregulated genes were direct targets of NF-kappaB transcription 
factors, we compared genome-wide p65 binding to DNA in control and cachectic 
muscle using chromatin immunoprecipitation-sequencing (ChiP-seq) . 
Bioinformatic analysis of ChiP-sequencing data from control and C26 muscles 
did not show p65 binding peaks in the upregulated genes as reflected by the 
expression arrays. The p65 ChiP-seq data are consistent with our finding of no 
iv 
significant change in protein binding to an NF-kappaB oligonucleotide in an 
electrophoretic mobility shift assay (EMSA), no activation of an NF-kappaB-
dependent reporter, and no effect of d.n. p65 overexpression in muscles of 
tumor-bearing mice. Taken together, these data support the idea that although 
inhibition of lkappaBalpha, and particularly IKKbeta, blocks cancer-induced 
muscle wasting , the alternative NF-kappaB signaling pathway is not required. In 
addition , the downstream NF-kappaB transcription factors are not involved in 
gene regulation during atrophy. These data are consistent with the growing body 
of literature showing that there are NF-kappaB-independent activities of IKKbeta 
and lkappaBalpha that regulate physiological processes. 
v 
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Introduction 
1.1 Cachexia 
Cachexia is a metabolic condition characterized by the severe wasting of 
both skeletal muscle and adipose tissue. The cachectic state is the result of 
abnormal metabolism [1 , 2] and thus differs substantially from that caused by 
calorie deprivation. While tissue wasting triggered by calorie restriction can be 
reversed by increasing caloric intake, tissue wasting caused by cachexia cannot 
be reversed by the consumption of extra calories. In addition, although 75% of 
the weight loss in starvation is the result of loss of adipose tissue, in cachexia , 
both muscle and fat are lost in equal amounts [1 , 3]. 
Cachexia is commonly associated with aging and with disease states such 
as chronic kidney disease, chronic heart disease, sepsis, Type I diabetes, HIV 
infection , and cancer, in particular, cancers of the lung and the upper Gl tract [1 ]. 
In addition to the increased muscle weakness and decreased resistance to 
fatigue expected from the loss of skeletal muscle, other effects of cachexia can 
include a compromised immune system, increased insulin resistance, increased 
glycerol turnover and depletion of essential fatty acids to support tumor growth , 
and an elevated resting energy expenditure due to increases in Cori cycle activity 
[1, 3, 4]. In the Cori cycle, lactic acid is converted to glucose and it is an 
extremely inefficient use of sugar leading to hypermetabolism. The Cori cycle 
normally accounts for only 20% of glucose turnover, but during cachexia , that 
percentage can increase to 50%. High rates of glycolysis take place during 
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cachexia despite the presence of oxygen [2]. Lung cancer patients typically 
experience an increase in resting energy expenditure, but gastric and colorectal 
patients typically do not [1 ]. 
1.2 Cancer cachexia 
Cachexia is estimated to increase cancer mortality rates by 30% [5] 
because patients are less able to tolerate therapeutic treatments such as 
chemotherapy. Despite the fact that cachexia increases the severity of any 
illness it accompanies, any treatment remains palliative. The more severe 
consequences of cachexia appear to arise from the loss of skeletal muscle and 
the associated health consequences mentioned above including intolerance to 
cancer treatment. Therefore , developing a better understanding of the cellular 
mechanisms underlying cachexia could lead to novel treatment strategies. 
1.3 Skeletal muscle atrophy 
Atrophy in adult skeletal muscle occurs by a reduction in the size of the 
muscle fiber rather than by a decrease in the number of fibers. The atrophy can 
occur by a decrease in the rate of the synthesis of muscle proteins, by an 
increase in the rate of the degradation of muscle proteins, or by a combination of 
both [6]. Muscle wasting in C26 tumor-bearing mice is characterized by 
decreased protein synthesis (-38%) and increased protein degradation (+131 %) 
[7]. During skeletal muscle atrophy, different myofibrillar proteins are broken 
down independently of one another. For instance, in the hindlimb muscles of 
mice implanted for 25 days with C26 tumors, myosin levels are reduced but actin 
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levels and other core myofibrillar protein levels are not affected [3, 8]. Myosin 
heavy chain (MyHCI) is decreased by 40% in Type II fibers but is not decreased 
in Type I fibers [9]. The targeting of specific components of the muscle structural 
scaffolding is not exclusive to cancer-induced cachexia; during denervation or 
fasting-induced skeletal muscle atrophy, myosin binding protein C (MyBP-C) and 
myosin light chain 1 and 2 (MyLC 1, MyLC2) are degraded prior to degradation of 
MyHC [1 0]. 
1.4 Proteolytic mechanisms 
Increases in the rate of protein degradation are generally attributed to the 
activity of four major degradative pathways: 1) the non-lysosomal, calcium-
dependent cysteine proteases which operate through calpains [11], 2) the 
lysosomal acid proteases which carry out autophagy through cathepsins B, D, H 
and Land degrade extracellular proteins by endocytosis [12, 13], 3) the cysteine 
proteases which carry out apoptosis through caspase activity [14], and 4) the 
ubiquitin-proteasomal pathway [13, 15-18]. 
1.4.1 Calpains 
Calcium-dependent cytosolic cysteine proteases (calpains) are known to 
bind to a-actinin to release actin and myosin from the sarcomeric Z-band [19] to 
regulate the degradation of titin, vinculin, C-protein, nebulin, desmin and 
tropomyosin and other myofibrillar proteins [11 ]. Calpains are known to regulate 
muscle protein degradation in dystrophies such as limb-girdle dystrophy [11, 20-
22], in a mouse breast cancer cell model [23], and in response to UV damage 
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[24]. However, the mRNA transcript levels of calpains were not changed in the 
skeletal muscles of human gastric cancer patients [2] or in Day 17 C26 tumor-
bearing mice [25], suggesting the lack of involvement of calpains in these two 
cancer types. By contrast, mRNA levels of m-calpain were increased in rats 
bearing the Yoshida ascites hepatoma at Day 5 post tumor inoculation [26], 
suggesting that different tumor types may regulate muscle wasting through 
different mechanisms. 
1.4.2 Cathepsins 
Cathepsins B, L, D, and H are known to degrade extracellular proteins 
through autophagy. Increases in mRNA levels of cathepsins were reported in 
human lung cancer patients [2], in 17 day C26 tumor-inoculated mice [25], in rats 
bearing the Yoshida ascites hepatoma [27] in Lewis lung carcinoma-bearing mice 
[28] and in C2C12 cells treated with C26 conditioned medium [29] . Increases in 
the activity levels of cathepsins were reported in cancer patients [1] and in rats 
inoculated for 4 days with the Yoshida ascites hepatoma [30]. Blockage of 
cathepsin activity caused only a slight reduction in tumor-induced muscle atrophy 
[30] so there may be other proteolytic mechanisms that play a more important 
role in tumor-induced atrophy. 
1.4.3 Caspases 
Caspases are intracellular cysteine proteases that promote the 
disassembly of cells during apoptosis. Increases in caspase activity have been 
reported with several types of tumors. Mice with MAC16 tumors causing 1-5% 
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total body weight loss had increases in caspase-1 activity (54%), caspase-8 
activity (84%), caspase-3 activity (98%), caspase-6 activity (151 %), and 
caspase-9 activity (166%) in the gastrocnemius muscles [31]. Mice with Lewis 
lung carcinoma and mice bearing B 16 tumors had increases in caspase-3 and · 
caspase-7 activity [32]. However, caspase-3 was not activated in humans with 
gastric cancer-induced cachexia [33], so caspases may not be involved in all 
types of cancer cachexias. 
Caspases proteolytic activity can complement other proteolytic 
mechanisms [34]. For example, in serum-deprived rat muscle cells, caspase-3 
breaks down actomyosin into smaller fragments that are then targeted for further 
breakdown by the proteasome [14] and caspases may mediate skeletal muscle 
wasting via the angiotensin system [6]. The precise role of caspases in tumor-
induced wasting is not understood . 
1.4.4 Ubiquitin-proteasome 
Ubiquitin-proteasome degradation is a major proteolytic mechanism for 
skeletal muscle proteins. Abnormal, foreign , misfolded or damaged proteins are 
targeted for degradation. Proteins are marked for degradation by a multi-step 
pathway involving first the activation of the carboxyl end of ubiquitin via an E1 
(ubiquitin-activating) enzyme, followed by the transfer of the activated ubiquitin to 
an E2 (Ub-carrier or Ub-conjugating) enzyme, and lastly, the linkage of the 
carboxyl end of ubiquitin to the epsilon amino group of lysines on the protein 
targeted for destruction via the activity of E3 (ubiquitin-ligase) enzyme. After a 
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chain of 5 or more ubiquitins have been attached to the targeted protein , the 
ubiquitinated protein is transported, unfolded and degraded by the 26S 
proteasome, a barrel-shaped multi-subunit protein complex [19, 35-38]. 
In yeast, one E1 ubiquitin-activating enzyme has been identified, but 11 
ubiquitin-conjugating enzymes have been identified and hundreds of ubiquitin-
ligase enzymes have been identified [35 , 39] . Mammalian species are known to 
have a greater number and a greater variety of both E2 ubiquitin-conjugating and 
E3 ubiquitin-ligase enzymes. Although the known E3 ubiquitin ligases are quite 
heterogeneous, they can be classified into at least three major groups by 
structural motifs: HECT (homologous to E6-associated protein C-terminus) , 
RING (really interesting new gene) or U-box (modified RING motif without full 
complement of Zn2+ binding ligands domain). Specificity for protein degradation 
appears to be conferred by the pairing of an E2 carrier protein with a specific E3 
ubiquitin ligase [13, 35, 39, 40] . Blocking the' activity of the 26S proteasome in 
an attempt to block skeletal muscle atrophy during cachexia may cause 
undesirable complications due to its ubiquitous function, but targeting the activity 
of a specific E2 ubiquitin-conjugating and E3 ubiquitin-ligase pair may open up 
new avenues for medical intervention [40]. 
1.5 Role of ubiquitin-proteasome during myotube atrophy due to cancer 
cell-conditioned medium 
Increases in the mRNA levels or protein levels of components of the 
ubiquitin-proteasome pathway are often used as an indicator of increased 
6 
proteolytic activity during tumor cell conditioned medium-induced myotube 
atrophy [29, 45] . For example, the E3 ubiquitin ligases atrogin-1/MAFbx and 
MuRF1 were reportedly upregulated in mouse myoblast (C2C12) cells treated 
with C26 cancer cell-conditioned medium, along with increased activity of the 
ubiquitin-proteasome pathway [29] . C2C12 cells treated with LLC cancer cell-
conditioned medium had upregulation of atrogin-1/MAFbx mRNA, but not MuRF1 
mRNA [45]. Increases in the 19S and 20S proteasomal subunits, and decreases 
in myosin protein were reported in mouse myotubes treated with extract from 
MAC-16 tumor cells [42]. Increases in levels of E3 ubiquitin ligases or of 
proteasomal subunits provide some evidence for increased proteolysis. 
1.6 Role of ubiquitin-proteasome during tumor-induced atrophy in vivo 
Increases in the mRNA levels or protein levels of components of the 
ubiquitin-proteasome pathway are also used indicators of increased proteolytic 
activity in vivo [13 , 41]. For instance, transcription of the E3 ubiquitin ligase 
atrogin-1/MAFbx is increased in C26 tumor-bearing mice as measured by RT-
PCR [8] and northern blot [43]. Zhou et al (201 0) also reported an increase in 
mRNA levels of the E3 ubiquitin-ligase MuRF1 . MuRF1 and atrogin-1/MAFbx 
mRNA were upregulated in 14-day LLC tumor-bearing mice [28] and in 21-day 
LLC-injected mice [44]. Transcription of E3 ubiquitin-ligases and E2 ubiquitin-
conjugating enzymes were increased in rats bearing the Yoshida ascites 
hepatoma [26, 27]. 14-day LLC tumor-bearing mice had increased atrogin-
1/MAFbx mRNA levels (4 fold) and atrogin-1/MAFbx protein levels (3 fold) , but no 
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increases in MuRF1 mRNA and protein levels [45]. 
Ubiquitin transcript levels and levels of ubiquitinated proteins also increase 
during tumor-induced skeletal muscle atrophy in vivo [13, 41]. The mRNA 
transcript levels of ubiquitin increased in rats bearing the Yoshida ascites 
hepatoma [26, 27], in mice bearing the Lewis lung carcinoma [46], and in C26 
tumor-bearing mice [25, 43]. R-1 C26 tumor-bearing mice had higher l'evels of 
ubiquitinated proteins even though there was no reported increase in E2 
ubiquitin-conjugating proteins [47]. 
In the same R-1 C26 tumor-bearing mice, proteasome activity did not increase 
with tumor load [47], but most other investigators have reported increases in the 
transcript and/or protein levels of subunits of the proteasome in the muscles of 
rodents following tumor inoculation. Increases in mRNA levels of proteasomal 
subunits were reported in the muscles of rats bearing the Yoshida ascites 
hepatoma [26, 27, 48], in mice bearing the Lewis lung carcinoma [48] and in mice 
bearing the C26 tumor [25]. Increases in the protein levels of proteasomal 
subunits were reported in the muscles of mice bearing C26 tumors [49] and in 
mice bearing the Lewis lung carcinoma [46, 50]. Increases in proteasome 
activity were reported in the muscles of mice bearing Lewis lung carcinoma for 
21 days and mice with 816 tumors for 16 days [32]. Torbafylline treatment, 
which blocks proteasome-dependent proteolysis, inhibits skeletal muscle atrophy 
in tumor-bearing rats [16]. 
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1.7 Triggers for tumor-induced atrophy: cytokines and tumor factors 
1.7.1 IL-6 
IL-6 is a cytokine that can induce atrophy in C2C12 myotubes in culture [51], and 
is believed to be a mediator of muscle wasting during cancer cachexia [1, 4, 6, 
29, 41]. Many investigators report increases in IL-6 plasma levels in C26 tumor-
bearing mice [1, 19, 20, 25, 29, 41, 43, 57-64]. Inhibition of IL-6 blocked 60% of 
C26 tumor-induced atrophy [25, 52-55], slowed the progression of cachexia in a 
murine uterine cancer model, and attenuated wasting in Ape mice, a murine 
model of colon cancer cachexia [2, 56]. However, continuous in vivo injection of 
IL-6 was not sufficient to induce cachexia, so other factors must be important in 
tumor-induced cachexia [55]. 
1.7.2 TNF-a 
Tumor necrosis factor-a (TN F-a) is a cytokine that is known to activate the 
NF-KB signaling pathway in both in vitro and in vivo models of skeletal muscle 
atrophy. Attempts to clarify its role in inducing cancer cachexia are inconclusive. 
Rats bearing Yoshida ascites hepatoma tumors had attenuation of skeletal 
muscle atrophy when treated with pentoxyfillane, which blocks TN F-a synthesis, 
or with suramin, which blocks TN F-a and IL-6 activity [4]. Rats bearing YAH 
tumors and treated with anti-TNF-a antibody had partial attenuation of cachexia 
on Day 4, but the effect was lost by Day 7 [65]. TN F-a receptor deficiency 
attenuated muscle atrophy in LLC tumor-bearing mice [50]. Cardiac patients 
treated with angiotensin-converting enzyme inhibitors had lower circulating levels 
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of IL-1, TN F-a and IL-6, and were less likely to have severe cachexia [66] . TN F-
a levels were elevated in the liver and spleen of LLC tumor-bearing female mice, 
but were not elevated in the serum. In these mice, treatment with a TN F-a 
blocking antibody did not attenuate muscle atrophy but did block lipid loss by 50-
85% [67]. TN F-a blocking antibody treatment also did not block muscle wasting 
in C26 tumor-bearing mice [52]. 
1.7.3 IL-1 
IL-1 is another cytokine associated with cancer-induced muscle wasting. 
Blocking IL-1 attenuated the protein degradation in response to endotoxin 
treatment [13], but use of IL-1 blocking antibody or IL-1 receptor antagonist had 
no effect on reversing cachexia in tumor-bearing rats [1 , 68]. Use of an IL-1 a 
receptor antagonist decreased IL-6 production in C26 liver-inoculated mice [60] 
and slightly attenuated cachexia in MCG 101 sarcoma-bearing mice [1] , but not 
in mice inoculated with C26 tumor cells subcutaneously [1]. The IL-1 blocking 
antibody treatment completely blocked tumor growth, but not muscle wasting , in 
C26 tumor-bearing mice [52]. 
1. 7.4 (Interferon gamma) IFN-y 
IFN-y is another cytokine implicated in tumor-induced cachexia. Mice with 
LLC tumors have elevated IFN-y levels, and treatment with an IFN-y blocking 
antibody attenuates cachexia in LLC mice and in mice with malignant 
mesothelioma [68]. Use of an IFN-y blocking antibody attenuated fat loss but not 
muscle loss in LLC tumor-bearing mice [1]. In another study, mice treated with 
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IFNy blocking antibodies prior to tumor inoculation showed inhibition of LLC 
tumor growth and did not lose weight from Day 0 to Day 15 post inoculation [69]. 
In C26 tumor-bearing mice, IFNy antibody suppressed cachexia , but did not 
suppress tumor growth [61]. Mice bearing the MCG 101 sarcoma and treated 
with an IFNy blocking antibody showed attenuation of weight loss and 
experienced a lengthened survivorship [1]. Taken together, IFNy seems to play 
a role in most types of cancer cachexia. 
1. 7.5 Proteolysis inducing factor (PI F) 
PIF is a glycoprotein that has been purified from MAC16 tumors and from 
the urine of 80% of pancreatic cancer patients [4] . . PIF activates pathways 
including NF-KB [4 , 6, 19, 70, 71]. PIF is sufficient to induce atrophy in mice and 
in murine myotubes via ubiquitin-proteasome degradation [4 , 21 , 29, 42, 71-73]. 
1.8 NF-KB signaling pathway 
Attempts to identify the signaling proteins and transcription factors that 
regulate cancer cachexia have yielded mixed results , but several signaling 
pathways have emerged as potential candidates. In this dissertation , I sought to 
clarify the role of NF-KB signaling and transcription in skeletal muscle during 
tumor-induced atrophy using primarily the Colon 26 carcinoma model in mice. 
focused on NF-KB signaling because studies from some laboratories have 
implicated the classical NF-KB signaling pathway, including ReiA, as a key 
regulator of muscle atrophy during tumor-induced cachexia [9, 59, 96, 98 , 99, 
1 00]. 
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NF-KB was first identified over a quarter of a century ago as a B-cell-
specific transcription factor bound to DNA at the enhancer region for the lgK light 
chain gene [74]. It was initially known for its role in regulating the immune system 
in response to bacterial or viral infection, and in response to inflammatory 
cytokines. Since the time of its discovery, the functions assigned to this family of 
transcription factors have expanded to include control over a diverse array of 
processes including cell differentiation, cell survival and cell proliferation, 
embryogenesis, homeostasis and physiological responses to physical and 
oxidative stresses [75]. 
1.8.1 NF-KB transcription factors 
There are five known mammalian NF-KB transcription factors: ReiA (p65) , 
ReiB, c-Rel , NF-KB1 (p105/p50) , and NF-KB2 (p100/p52). The transcription 
factors in this family share in common a Rei homology domain (RHO) at the N 
terminus that is approximately 300 amino acids in length and has residues for 
dimerization , nuclear localization, and DNA binding. ReiA (p65) , ReiB and c-Rel 
have at least one transactivation domain at the C terminus, so are able to induce 
transcription. NF-KB1 (p1 05/p50) and NF-KB2 (p1 OO/p52) lack the transactivation 
domain at the C terminus but have a series of ankyrin repeats at the C terminus. 
The ankyrin repeats repress the formation of active Rei complexes, similar to 
IKBs [24, 76-78]. 
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1.8.2 Dimerization and NF-KB transcription factor DNA binding 
The dimerization residues in the Rei homology domain of all the NF-KB 
transcription factors (except p52) are highly conserved and consist of 
symmetrical beta-strands that allow efficient dimerization. There are at least 15 
known stable pairings, and slight differences in their amino acid structures cause 
some dimer pairings to be more stable than others. Of all the stable 
combinations, 12 dimers are known to localize to the nucleus and bind DNA to 
regulate transcription . The consensus KB DNA binding sequence is as follows: 
5'-GGGRN W YYCC-3'. Because of the presence of a histidine residue in a 
particular location , both p50 and p52 transcription factors preferentially bind the 5' 
end of the KB consensus sequence. An alanine instead of histidine confers 
preferential binding to the 3' end of the consensus sequence for ReiB, p65 and c-
Rel. Certain dimer combinations preferentially associate with different 
permutations of the DNA binding sequence. For instance, p65 and c-Rel 
homodimers prefer a 9 base-pair sequence, whereas p52 and p50 homodimers 
prefer to bind an 11 base-pair sequence with an adenine directly in the middle of 
the sequence. Perhaps the most common pairing is the p65/p50 heterodimer 
that binds either a 10 or 11 base-pair consensus sequence with equal affinity [24, 
79]. 
1.8.3 Post-translational modifications of NF-KB transcription factors 
Post-translational modifications of the NF-KB transcription factors , such as 
by phosphorylation , acetylation , ubiquitination, nitrosylation , pro_line 
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isomerization , methylation , or cysteine oxidation , can also play a role in 
determining transcription factor activity. 
1.8.3.1 Post-translational modifications of p65 
Phosphorylation of p65 is often associated with transcription factor 
activation and may also have an effect on dimerization preferences. For 
instance, phosphorylation at Serine 276 in the RHO triggers protein 
conformational changes that allow more efficient binding to CBP/p300 co-factors , 
inhibit p65 binding to IKBa, increase nuclear p65 levels, all of which tend to 
increase transactivation potential. Phosphorylation at Serine 529 in the 
transactivation domain increases DNA binding. Phosphorylation at Serine 536 
appears to affect how transient or sustained the NF-KB response is by 
determining the length of time IKB is retained in the cytoplasm. Phosphorylation 
at Threonine 435 and 505 in the TAD2 terminates the NF-KB response by 
increasing the association with histone deacetylases. Phosphorylation at Serine 
468 can either have stimulatory or inhibitory effects on transcription [24, 78]. 
Acetylation of p65 by the histone acetyl transferases (HAT) CBP and p300 
can either promote or inhibit transcription of NF-KB-dependent genes. For 
instance, acetylation at Lysine 122 and Lysine 123 decreases the binding affinity 
of p65 to the DNA consensus sequence, and promotes the binding of p65 to 
lkBa, both of which decrease effective NF-KB activity. Conversely, acetylation at 
Lysine 218 and Lysine 221 enhances p65 binding to DNA and inhibits the binding 
of p65 to IKBa, thereby preventing its export from the nucleus, thereby promoting 
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NF-KB-dependent activity. Acetylation at Lysine 310 appears to be increased 
when Serines 276 and 536 are phosphorylated, and acetylation at Lysine 310 
enhances transactivation potential of p65 [24, 78]. 
Methylation of p65 at Lysine 37 and Lysine 218/221 promotes p65 binding 
to DNA. Proline isomerization of p65 inhibits p65 binding to IKB and promotes an 
increase in nuclear levels of p65. Cysteine oxidation of p65 inhibits DNA binding , 
promotes the dissociation of p65 from p50, and causes p65 to increase 
association with cytoplasmic IKB [24]. 
1.8.3.2 Post-translational modifications of ReiB 
Post-translational modifications of the other NF-KB transcription factors 
also regulate NF-KB signaling activity. For instance, phosphorylation of ReiB at 
Serine 368 in the RHO stabilizes its dimerization with p52. Phosphorylation of 
ReiB at Threonine 84 and Serine 552 induces proteolysis [24] . 
1.8.3.3 Post-translational modifications of c-Rel 
Oxidation of Cysteine 27 in the RHO of c-Rel decreases its binding affinity 
for DNA and the phosphorylation of multiple serines in the TADI of c-Rel permits 
ubiquitination and promotes proteolysis of c-Rel [24]. 
1.8.3.4 Post-translational modifications of NF-KB1/p1 05/pSO 
Post-translational modifications of NF-KB1 can regulate NF-KB dependent 
activity because modifications that trigger the partial hydrolysis of p1 05 to p50 
allow p50 to dimerize, translocate to the nucleus, bind DNA, and either promote 
or repress the transcription of NF-KB-dependent genes. For instance, oxidation 
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of p1 05/p50 at Cysteine 62 in the RHO inhibits DNA binding, but phosphorylation 
of p1 05/p50 at Serine 337 in the RHO enhances DNA binding. Phosphorylation 
of p 1 05 at Serines 903 and 907 by GSK313 stabilizes p 1 05 at rest, but 
phosphorylation of Serines 927 and 932 induces ubiquitination of p1 05 at 
multiple lysines in the ankryin-rich region , stimulating the complete degradation 
of p105. Acetylation of p105/p50 at Lysines 431 , 440 and 441 enhances DNA 
binding [24]. Thus, the activity of p50 is greatly impacted by post-translational 
modifications. 
1.8.3.5 Post-translational modifications of NF-KB2/p1 OO/p52 
Likewise, post-translational modifications of NF-KB2/p1 00 regulate the 
processing of p1 00 to its smaller, active form , p52, to promote or repress the 
transcription of NF-KB-dependent genes. For instance, phosphorylation of 
p100/p52 by IKKa at Serines 99, 108, 115, and 123 regulate p100 processing to 
p52 , and may also regulate p52 dimerization and DNA binding . Acetylation of 
p100/p52 by p300 at an unknown site increases the processing of p100 to p52 
and increases DNA binding activity. Phosphorylation of p1 00 at Serines 866, 
870, and 872 by IKKa triggers the ubiquitination of p1 00 at Lysine 856, leading to 
degradation of p1 00 [24]. All of these post-translational modifications lead to 
partial proteolysis of p1 00 and allow p52 to bind DNA and either repress or 
activate NF-KB-dependent genes in the nucleus. 
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1.8.4 NF-KB signaling proteins: the IKK complex 
Upstream of the NF-KB transcription factors are the NF-KB signaling 
proteins including the IKK complex, consisting of three proteins: IKKa, IKKI3, and 
the essential modulator subunit (NEMOIIKKy) [78]. IKKa and IKKI3 share 52% 
homology [80]. Both IKK signaling proteins have an N terminal catalytic domain 
that has kinase activity when phosphorylated, as well as a leucine zipper domain 
(LZ), a helix-loop-helix domain (HLH), and a NEMO-binding domain (NBD) [80]. 
If the LZ, HLH, and NBD domains are deleted, IKKI3 has no activity, but IKKa 
retains its kinase activity. If only the NBD is deleted, the IKKs have constitutive 
activity. If the C-terminus of IKKa is exchanged for the C-terminus of IKKI3, IKKa 
behaves like IKKI3 [80]. 
NEMO, the third member of the IKK complex, has two N-terminal coiled-
coil domains (CC1 and CC2), as well as a leucine zipper domain (LZ) and a zinc 
finger domain. The first 37 amino acid residues of CC1 are required for NEMO to 
bind the IKKs. IKKI3 binds NEMO with greater affinity than IKKa. The CC2 
domain and the LZ domain are required for oligomerization of NEMO and contain 
residues that permit the ubiquitination of NEMO. The C-terminus of NEMO 
interacts with upstream signaling proteins and regulates the activation of the 
IKKs. At rest, NEMO is bound to IKKa and IKKI3 in the cell cytoplasm [80]. 
1.8.5 Post-translational modifications of IKK complex signaling proteins 
Post-translational modifications of the signaling proteins in the JKK 
complex affect NF-KB activity. For instance, phosphorylation of JKKa at Serines 
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176 and 180 and I KKI3 at Serines 177 and 181 are essential for activation. 
Substitution of those serines with the non-polar amino acid alanine prevents 
activation. Substitution of those serines with glutamic acid , which mimics 
phosphorylation, results in constitutive IKK kinase activity. During kinase 
activation , Lysine 44 in the catalytic domain of both IKKa and IKKI3 is an ATP 
binding site. Nitrosylation at Cysteine 179 inhibits IKKI3 activity, and TNF 
treatment denitrosylates Cysteine 179 to permit IKKI3 activation [24, 78]. 
Phosphorylation of NEMO at Serine 68 negatively regulates the IKK 
complex. NEMO sumoylation at Lysine 277 and ubiquitination at the same 
residue is essential for the activation of the IKK complex. Lysine 309 near the C 
terminal leucine zipper domain of NEMO can be ubiquitinated and sumoylated in 
response to DNA damage. Lysine 399 and an unknown lysine in the C-terminal 
zinc finger domain of NEMO can be ubiquitinated. Deletion of both the leucine 
zipper and the zinc finger domains results in constitutive IKKI3 binding [24, 78] . 
1.8.6 Classical NF-KB pathway signaling 
Two major NF-KB signaling pathways have been identified: the classical or 
canonical NF-KB signaling pathway, and the nonclassical or alternative NF-KB 
signaling pathway. In the classical pathway, stimuli such as TNF-alpha or IL-1 
trigger a series of upstream kinases and receptor associated proteins that 
activate the IKK complex. When activated, NEMO is ubiquitinated , leading to 
conformational changes that trigger the phosphorylation of IKKI3 at two serines in 
the activation loop. IKKI3 has kinase activity, and it phosphorylates NEMO at 
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Serine 68 triggering the dimerization of NEMO and the release of the IKKs. IKKP 
also phosphorylates IKBa at Serines 32 and 36,, leading to the ubiquitination and 
degradation of IKBa by the proteasome [78, 81]. 
IKBa belongs to a family of proteins that regulate NF-KB binding to DNA. 
Members of the IKB family share a common structural motif, a sequence of 6-10 
ankyrin repeats. The ankyrin repeats loosely bind and mask the nuclear 
localization sequences on NF-KB transcription factors. PrototypicaiiKBs are thus 
able to sequester the NF-KB transcription factors in the cell cytoplasm and inhibit 
NF-KB-dependent transcriptional activation. Some of the atypical IKBs are found 
primarily in the nucleus, rather than the cytoplasm and may activate rather than 
repress transcription [76]. 
At rest, IKBa preferentially binds p65/p50 heterodimers and retains them in 
the cell cytoplasm. Upon activation of NF-KB classical pathway signaling, IKBa is 
degraded by the proteasome, and the bound KB dimers are released, exposing 
the nuclear localization sequence in the RHO of the NF-KB transcription factors. 
The dimers translocate to the nucleus and bind DNA at KB consensus binding 
sequences, generally activating the rapid transcription of NF-KB-dependent 
genes such as those controlling the immune response and the production of pro-
inflammatory cytokines [24, 77, 78, 80-86]. The classical pathway can be de-
activated by the NF-KB-dependent re-synthesis of IKBa, IKB~, IKB£, NF-KB1 or 
NF-KB2 leading to the nuclear translocation of IKBs or IKB-Iike signaling proteins, 
the binding of IKBs to NF-KB transcription factors, and subsequent nuclear 
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exportation of NF-KB transcription factors back to the cytoplasm [78]. 
1.8.7 Alternative NF-KB pathway signaling 
In the alternative pathway, stimuli such as CD40, B-cell activators of the 
TNF family (BAFF), lipopolysaccharide (LPS), latent membrane protein of the 
Epstein-Barr virus (LMP-1), and lymphotoxin-P bind to membrane receptors, 
recruit and activate NF-KB-inducing kinase (NIK). NIK phosphorylates IKK 
homodimers, leading to the phosphorylation and processing of p1 00 to p52. The 
processing of p1 00 to p52 allows p52 to dimerize with ReiB and trans locate to 
the nucleus leading to the slow but persistent activation of genes such as those 
responsible for the maintenance and development of lymphoid organs [78, 84, 
87]. 
1.8.8 Other isoforms of IKB (Inhibitor of KB) 
In addition to IKBa, there are other isoforms of IKB including, but not 
limited to, IKB~, IKBO, IKBE, IKBy, IKBs, IKBNS, IKBL, IKBrJ, and Bcl-3. The IKB 
isoforms have ankyrin repeat domains (ARD) [80, 88] and differ primarily in their 
rates of degradation and resynthesis [79] and these differences allow for 
differential regulation of gene expression. For instance, in the classical pathway, 
newly synthesized IKBa enters the nucleus, binds KB transcription factors, and 
transports them back to the cytoplasm. The rapid degradation and rapid re-
synthesis of IKBa, and the rapid shuttling of IKBa and the KB transcription factors 
into and out of the nucleus, allows for a rapid, but highly transient regulation of 
NF-KB-dependent genes [79]. The transcriptional activity generally lasts 1-4 
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hours in most cells [89]. Some of the IKB isoforms have overlapping functions 
and their activity can be taken over by other isoforms, but other isoforms are 
necessary and their absence results in severe defects and lethality. For 
instance, deletion mutants of IKBa die 7-8 days after birth due to defective B cell 
response, immune deficiencies, severe inflammatory dermatitis, altered lymph 
node architecture, atrophy of the spleen and the thymus, and granulocystosis 
[88 , 90]. 
IKBj3 appears to regulate persistent NF-KB activity and does not appear to 
be NF-KB inducible. It is known to bind p65/c-Rel heterodimers with higher 
affinity than IKBa and does not allow them to shuttle back and forth to and from 
the cytoplasm. Unlike IKBa, which is degraded and re-synthesized rapidly and 
which regulates transient NF-KB activation, IKBj3 is less sensitive to degradation 
and undergoes very slow re-synthesis. It can compete with IKBa for NF-KB 
transcription factor binding but bound dimers are still able to translocate to the 
nucleus and bind DNA. IKBj3 knockout mice are viable and only have minor 
defects in the immune system [80, 88]. 
IKB£ interacts with p52. Like IKBa, IKB£ shuttles actively between the 
nucleus and the cytoplasm, and it is phosphorylated at N-terminal serines by the 
IKK complex and degraded in an IKK-dependent manner. However, the rate of 
its degradation and resynthesis is much slower than that of IKBa, and it appears 
to regulate late, transient genes mostly in hematopoietic cells [80]. Some 
evidence suggests that IKBa and IKB£ operate anti-phase to each other [79], but 
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in the absence of IKB£, IKBa can take over its functions, so deletion mutants do 
not show any apparent defects in NF-KB activation [86, 88, 90]. 
IKBs has strong structural similarity to Bcl-3. It is primarily nuclear, is 
expressed weakly at basal levels, but is rapidly induced. IKBs interacts with p50 
homodimers and associates with the promoter region of IL-6. It may negatively 
regulate p65. Deletion of the transactivation domain results in loss of NF-KB-
dependent activity. IKBs deficient mice are viable but have severe dermatitis and 
defects in IL-6 production . Overexpression of IKBs results in increased 
expression of IL-6 and decreased expression of TN F-a [76, 88]. 
IKBy also binds p50 homodimers, and its sequence is more similar to Bcl-3 
than to the other IKBs. Like Bcl-3, it has multiple sites for ubiquitination but its 
function is not yet well understood [80]. 
IKBNS consists of six ankyrin repeats and a short N and C terminus, and 
has no known transactivation domain. It is known to bind cytoplasmic and 
nuclear p50, as well as nuclear p52, p65, ReiB and c-Rel. IKBNS-deficient mice 
have severely impaired immune responses. IKBNS appears to be important for 
the termination of production of IL-6 [76] . 
IKBr] appears to be similar in function to IKBs but there have not been any 
known knockout studies yet to determine the functional overlap of those two 
IKBs. IKBr] consists of 8 ankyrin repeats and it is unique in possessing a long 
carboxyl end tail. It is known to interact with p50, but not with p65, and siRNA 
knockout studies show that it is essential for the expression of IL-6, 11-1 (3, and 
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IFNP [76]. 
IKBL has two isoforms, a(L) and a(S) and is localized to the nucleus. It 
has the typical ankryin repeats found in the other members of the IKB family, and 
it is known to suppress the expression of the NF-KB-dependent target genes, 
TN Fa and IL-6. However, because it is not yet known to associate with any of 
the Rei transcription factors , there is some debate over whether this protein is 
truly part of the IKB family [76]. 
Bcl-3 has a 7 -ankyrin repeat domain and two transactivation domains, and 
both are essential for full transcriptional activity. It was first identified for its 
oncogenic potential in repressing the activity of tumor suppressor p53 and 
enhancing proliferation. It preferentially associates with p50 and p52 hetero- and 
homodimers in the nucleus. Binding p50 or p52 homodimers may reverse their 
transcriptional repression and allow transcriptional activation [76]. When present 
in the cytoplasm, Bcl-3 competes with p1 05 for binding to p50. Bcl-3 knockout 
mice have defects in the spleen , T cell differentiation, and humoral immune 
system responses [76, 80, 86, 88]. Bcl-3 plays a key role in skeletal muscle 
atrophy during unloading-induced atrophy [91-95] but its involvement in C26 
tumor-induced skeletal muscle atrophy is not known. 
1.8.9 Post-translational modifications of IKBs 
IKB family members are also regulated by post-translational modifications. 
Sumoylation of Lysine 21 on IKBa inhibits ubiquitination at Lysines 21 and 22 and 
may enhance its nuclear export. Phosphorylation of IKBa at Serines 32 and 36 
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overrides the effects of sumoylation at Lysine 21, and permits ubiquitination and 
the subsequent targeting of this signaling protein for proteasomal degradation. 
Phosphorylation of C-terminal serines in the PEST domain (a region rich in 
proline, glutamate, serine and threonine) are also associated with IKBa protein 
degradation [24]. Phosphorylation of Serines 19 and 23 on IKB~ lead to 
ubiquitination at Lysines 6 or 9. Because phosphorylation at Serines 19 and 23 
on IKB~ is less efficient than the phosphorylation of homologous sites on IKBa, 
ubiquitination and subsequent degradation of IKB~ are also less efficient than 
that of IKBa [24]. 
1.8.1 0 Role of NF-KB signaling proteins and transcription factors in 
tumor-induced skeletal muscle atrophy 
Prior work has suggested the involvement of the NF-KB signaling pathway 
in regulating tumor-induced cachexia . For example, phospho-p65 is elevated in 
the muscles of C26 tumor-bearing mice [9] and is elevated 25% in patients with 
pancreatic cancer, accompanied by a 25% decrease in IKBa protein levels [96] . 
NF-KB is increased in cells treated with proteolysis inducing factor (PIF) extracted 
from tumor secretions [73]. Muscles of mice treated with PIF isolated from 
MAC16 tumors showed rapid degradation of IKBa and increased nuclear 
localization of NF-KB [4]. NF-KB binding activity was increased in the 
gastrocnemius muscles of mice treated with PIF extracted from MAC16 tumors 
[42]. An EMSA using an NF-KB probe showed increased binding in C26 tumor-
bearing mice [9]. And EMSA using a different NF-KB probe showed increased 
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binding in LLC tumor-bearing mice at Day 14 post inoculation [97]. A six-fold 
increase in NF-KB activity was shown by ELISA in the muscles of LLC tumor-
bearing mice [98]. 
Inhibition of NF-KB signaling, either by blocking transcription factor activity 
or blocking signaling protein activity, also points to the involvement of NF-KB in 
tumor-induced skeletal muscle atrophy. For example, when a decoy NF-KB 
oligonucleotide sequence was injected into C26 tumor-bearing mice, 
gastrocnemius muscle atrophy and lipid loss were attenuated, though tumor 
growth was not affected [59]. In rats bearing Yoshida ascites hepatoma 130 
tumors, use of an NF-KB/AP-1 inhibitor blocked muscle wasting [99]. Treatment 
for 48 hours with DHMEQ, another NF-KB inhibitor, attenuated gastrocnemius 
muscle mass loss and epididymal fat pad loss in Balb/c mice bearing JCA 1 
tumors [1 00]. 
Overexpression of a trans-dominant negative IKBa (the super repressor) 
partially restored differentiation in PC3 myoblasts treated with conditioned 
medium from a prostate cancer cell line, as measured by scoring the ratio of 
nuclei in myosin positive myotubes to the total number of nuclei in randomly 
selected fields [1 01]. Overexpression of the IKBa super repressor in C2C 12 
murine myoblasts blocked atrophy in cells treated with PIF [70]. Muscle-specific 
overexpression of the IKBa super repressor (SS32/36AA) in genetically altered 
mice inoculated with LLC tumors attenuated skeletal muscle mass loss and lipid 
loss and increased survivorship [98]. 
25 
Administration of resveratrol , which blocks IKBa activity, significantly 
attenuated cachexia as measured by total body mass or muscle mass, and/or 
tumor growth in MAC16 tumor-bearing mice [42] , in C26 tumor-bearing mice 
[1 02] , in LLC tumor-bearing mice [1 03], in rats with Yoshida ascites hepatoma 
[1 04] , in rats with AH 1 09A hepatoma [1 05], and in mice with H22 hepatoma [1 06, 
1 07]. However, oral administration of resveratrol had no effect on leukemia or 
lung cancer [1 03]. 
1.9 Conclusions 
These data show that further investigation into the involvement of NF-KB 
signaling in tumor-induced cachexia is warranted. Prior work suggests the 
involvement of NF-KB, however, identification of the signaling proteins and the 
transcription factors that regulate muscle wasting is far from complete. In 
addition, the signaling pathway by which skeletal muscle wasting is induced may 
depend on factors such as tumor type, muscle fiber type (fast or slow), location of 
tumor inoculation , length of time from tumor implantation , and gender. The 
purpose of this work was to identify the NF-KB signaling proteins and NF-KB 
transcription factors that regulate muscle wasting due to cancer. A second 
purpose was to identify the NF-KB target genes ori a genome-wide level in order 
to determine if an NF-KB transcriptional network regulates cancer-induced 
muscle wasting . 
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Chapter 2 Methods 
Ethics Statement 
This study was carried out in strict accordance with the recommendations in 
the Guide for the Care and Use of Laboratory Animals of the National Institutes 
of Health. The protocol was approved by the Charles River Campus Boston 
University Institutional Animal Care and Use Committee (protocol number: 12-
016). All surgery was performed under ketamine/xylazine anesthesia, and all 
efforts were made to minimize suffering. All personnel working with animals 
have undergone mandatory IACUC training and yearly review: 
http://www.bu.edu/orctraining/animal/lacf/. 
2.1 Cells 
Colon 26 (C26) adenocarcinoma cells (National Cancer Institute, Frederick, 
MD) were plated and maintained at 3rC, 5% C02 in Dulbecco's Modified Eagle 
Medium, high glucose (Invitrogen, Carlsbad, CA, USA) supplemented with 10% 
fetal bovine serum (Invitrogen), 1% penicillin-streptomycin (Invitrogen), and 1% 
L-glutamine (Invitrogen). Prior to inoculation into mice, C26 cells were 
trypsinized and washed twice with phosphate buffered saline and then re-
suspended in a 1:1 solution of 1 X PBS and matrigel (BD Biosciences, San Jose, 
CA, USA). 
2.2 Animals 
Eight-week-old, male CDF1 mice purchased from Charles River 
Laboratories (Wilmington, MA, USA) were used for all experiments. Mice were 
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treated in strict accordance with the recommendations in the Guide for the Care 
and Use of Laboratory Animals of the National Institutes of Health . Animals were 
maintained on a 12:12 LID cycle, were housed individually, and were given 
access to food and water ad libitum. After three days of acclimation , animals 
were randomly assigned to a non-tumor control group or a C26 tumor-bearing 
group. Control animals received an inoculum of 150 J..IL 1 x PBS/matrigel (1 :1) 
subcutaneously into the right and left flanks. Tumor-bearing animals received an 
inoculum of 5.0 x 105 C26 cells suspended in 150 J..IL PBS/matrigel (1: 1) injected 
subcutaneously into the right and left flanks ; this was performed on lightly 
anesthetized mice (40 mg/kg ketamine + 5 mg/kg xylazine). 
2.3 Plasmid DNA injection into muscle 
Plasmid DNA was isolated using the QIAGEN Endotoxin-Free Mega Kit as 
per manufacturer's instructions. Plasmid DNA was injected into muscle 1 0 days 
following the tumor inoculations, as described previously [1 08] . Briefly, the 
plasmid DNA was ethanol-precipitated and re-suspended in 0.45% sterile 
saline/ddH20 . All mice receiving surgery were given prophylactic treatments with 
0.1 mg/kg Buprenorphine injection prior to surgery. Mice were anesthetized with 
ketamine (80 mg/kg) and xylazine (10 mg/kg) . The tibialis anterior (TA) muscles 
from each animal were injected with 35 J..lg of expression plasmid in 25 J..IL of 
0.45% sterile saline using a 29-gauge insulin syringe. Following the plasmid 
injection , muscles were stimulated with a low voltage electrical current using two-
paddle electrodes [1 09] that delivered 6 pulses at 86 V/cm for 20 ms with an 
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interpulse interval of 200 ms (Electro Square Porator ECM 830, BTX). This is a 
low-dose electroporation protocol that does not induce damage [110-112]. At 
day 25 post-inoculation , TA muscles were removed from both control and C26 
tumor-bearing mice, weighed , and either snap-frozen in liquid nitrogen for 
biochemical analysis or mounted on tongue depressors, embedded in tissue-
freezing medium, and frozen in liquid nitrogen-cooled isopentane for 
histochemical analysis. Injection of the NF-KB reporter plasmid was done on the 
same day as tumor cell inoculation. Injection of d.n. p65-EGFP was done on day 
6 after tumor inoculation. 
2.4 Plasmids 
The expression plasmids used were the following: constitutively-active (c.a.) 
IKKa-EGFP, c.a. IKKI3-EGFP, dominant-negative (d.n.) IKKa-EGFP, d.n. IKK13-
EGFP, IKBaSR-EGFP, d.n. NIK-GFP, d.n. p65-EGFP, and d.n. c-Rei-EGFP. The 
c.a. IKKa-EGFP (SS176/180EE) and c.a. IKKI3-EGFP (SS177/181EE) encode 
EGFP fusion proteins of constitutively active forms of IKKa and IKKI3 wherein 
glutamic acid residues mimic phosphorylation of two key serines in the catalytic 
domain as described in [108] . The d.n. IKKa-EGFP (K44M) and d.n. IKKI3-EGFP 
(K44M) expression plasmids encode EGFP fusion proteins of kinase-dead forms 
of IKKa and IKKI3 that we have described in detail [108]. We also constructed 
the IKBaSR-EGFP fusion plasmid that we have described in detail [94]. The d.n. 
p65 (313) is a truncated form of p65 missing the C-terminal transactivation 
domains and was a gift from D. Guttridge [113]. We created a d.n. p65-EGFP 
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fusion plasmid by cloning the N-terminal 313 amino acid-coding DNA sequence 
of p65 into the Hindiii-Sall sites of pEGFP-N1 (313+238 = 551 a.a.) . We verified 
the cloning by sequencing the plasmid and tested the dominant-negative function 
in C2C12 myotubes, in which the d.n. p65-EGFP was able to block the TNFa 
activation of an NF-KB reporter by 92% (Figure 51). 
For the creation of a d.n. c-Rei-EGFP plasmid, we used a mouse c-Rel 
template, a gift from T. Gilmore, copying the nucleic acid sequence for the Rei 
homology domain of the gene containing a.a. 1-288 (missing the two C-terminal 
transactivation domains) and adding restriction sites to clone the fragment in-
frame into the EcoRI-Kpnl sites of pEGFP-N1. The resulting d.n. c-Rei-EGFP 
insert was checked by sequencing and functioned as a dominant-negative Rei 
because its expression blocked NF-KB activation in C2C12 myotubes (Figure 
51). The d.n. NIK-GFP expression plasmid , a gift from A. Kumar, encodes a 
kinase dead form of NIK and EGFP from a separate cistron [114]. 
2.5 Immunohistochemistry 
Tibialis anterior (TA) muscle fiber cross-sectional areas of plasmid 
transfected fibers (expressing green fluorescence fusion proteins) were 
compared to fibers areas in the same fields that did not take up the plasmid in 
both tumor-bearing and control mice. As previously described [1 08], frozen 
sections were taken from the mid-belly of theTA (7.5 1-1m-thick), mounted on 
Tissue Tack microscope slides (Polysciences, Inc, Warrington, PA, USA) and 
fixed in 4% paraformaldehyde. Cross sections were washed , blocked in 10% 
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BSA and incubated with rabbit anti-laminin 1 :200 (L9393; Sigma-Aldrich) in 1% 
BSA followed by a Texas Red-X goat anti-rabbit lgG fluorescent dye-conjugated 
secondary antibody 1:200 (T-6391; Invitrogen). Sections were mounted on a 
coverslip with Vectashield mounting medium (Vector Laboratories, Burlingame, 
CA, USA). Images were visualized at 20X magnification using an inverted light 
microscope (Nikon Eclipse TS 1 00). All images were captured with a SPOT RT 
camera (Diagnostic Instruments, Sterling Heights, Ml, USA). Fiber cross-
sectional area was calculated using the Meta-Morph Imaging System (Universal 
Imaging, Glendale, WI , USA). The average number of fibers measured per 
muscle was 200. 
2.6 Isolation of crude nuclear extracts 
Crude nuclear extracts from hind limb muscles of 12 to 23 day C26-
inoculated CD2F1 male mice and age matched controls were isolated according 
to Kumar and Boriek [115] with some modifications. All isolation steps and spins 
were carried out at 4 oc using chilled buffers. Flash frozen muscles were 
suspended at 1 mg muscle weight per 18 IJI of buffer (1 0 mM HE PES [pH 7.9] , 
10 mM KCI, 3 mM MgCI2 , 0.1 mM EDTA [pH 8], 0.1 mM EGTA, 0.1% Triton X-
1 00, 1 mM dithiothreitol , 0.5 mM phenylmethylsulfonyl fluoride, and protease 
inhibitor cocktail) and immediately homogenized on ice. Homogenized muscles 
were incubated on ice for 5 min followed by 20 s of vigorous vortex. Nuclei were 
spun at 3000 x g for 10 min. The supernatant was then removed and was stored 
at -80°C. Nuclear pellets were washed with 1 ml of modified cytoplasmic extract 
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buffer without Triton X-1 00 and centrifuged at 3000 x g for 3 min. Pellets were 
resuspended in 4 Ill of nuclear extract buffer (20 mM HEPES [pH 7.9] , 420 mM 
NaCI, 1 mM EDTA, 1 mM EGTA, 25% glycerol , 1 mM dithiothreitol , 0.5 mM 
phenylmethylsulfonyl fluoride, and protease inhibitor cocktail) per mg of original 
muscle weight. Re-suspended nuclear pellets were incubated on ice for 30 min 
with 15 s of vigorous vortexing every 10 min. Samples were centrifuged at 
16,000 x g for 20 min and nuclear extract (supernatant) was removed and stored 
at-80°C. 
2.7 Electrophoretic mobility shift assay (EMSA) 
Protein concentration of crude muscle nuclear extracts was determined 
using the Bradford assay (Bio-Rad Protein Assay Dye Reagent, Bio-Rad 
Laboratories, Hercules, CA, USA). Double stranded NF-KB IRDye 700 infrared 
dye end-labeled oligonucleotide, 5'-AGTIGAGGGGACTITCCCAGGC-3' 
(underline indicates NF-KB binding site) , was purchased from LI-COR 
Biosciences (Lincoln , NE, USA). Consensus unlabeled competitor NF-KB 
oligonucleotide was purchased from Integrated DNA Technologies, Inc. 
(Coralville, lA, USA). EMSA binding reaction was performed using Odyssey 
EMSA Buffer Kit (LI-COR Biosciences) with some modifications. Total reaction 
volume was prepared in 20 1-11. Binding reaction reagents were added to purified 
water in the following order: 2 1-11 of binding buffer (1 00 mM Tris, 500 mM KCI, 10 
mM DTI; pH 7.5), 2 1-11 of 25 mM DTI/2.5% Tween-20, 1 1-Jg/1-JI poly dl•dC in 10 
mM Tris , 1 mM EDTA; pH 7.5, 50 fmole NF-KB IRDye 700 infrared dye end-
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labeled oligonucleotide, and 15-20 f.lg nuclear extract. In reactions with 
unlabeled NF-KB competitor, unlabeled and labeled oligonucleotides were mixed 
prior to addition to the binding reaction. Binding reactions were gently mixed and 
incubated for 25 min , at room temperature, in the dark. Prior to loading samples, 
2 1-11 of Orange Loading Dye (65% w/v sucrose, 10 mM Tris-HCI pH 7.5, 10 mM 
EDTA, 0.3% w/v Orange G) was added to the 20 1-11 reaction and gently mixed. 
DNA-protein complexes were separated from free oligonucleotide on non-
denaturing 5% Tris-borate-EDTA, PAGE Ready Gels (Bio-Rad Laboratories, 
Inc.) . Samples were electrophoresed at 76 V for 2 hat room temperature in the 
dark. Protein bound to labeled oligonucleotide complexes were visualized using 
an Odyssey Infrared Imager (LI-COR Biosciences). 
2.8 NF-KB-dependent reporter activity 
At the indicated time points, TA muscles transfected with an NF-KB-
dependent luciferase reporter were harvested and then homogenized in 1 mL 
Passive Lysis Buffer (Promega, Madison, WI) with protease and phosphatase 
inhibitors (Roche Applied Science, Indianapolis, IN). Homogenates were 
centrifuged at 5,000 x gat 4°C for 20 min. Supernatant was collected and mixed 
with Luciferase Assay Reagent (Promega) according to manufacturer's 
instructions. Luciferase activity was measured by a TD-20/20 luminometer 
(Turner Designs, Sunnyvale, CA, USA). 
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2.9 Western blot analysis 
Protein concentration of muscle lysates in passive lysis buffer was 
determined using the Bradford assay (Bio-Rad Protein Assay Dye Reagent, Bio-
Rad Laboratories, Hercules, CA). Fifty to 75 micrograms of protein was 
denatured and size fractionated on 4-15% SDS-polyacrylamide gels. Proteins 
were transferred to an lmmobilon-FL polyvinylidene fluoride membrane (Millipore, 
Bedford , PA, USA), blocked in Odyssey blocking buffer (LiCor Biotechnology, 
Lincoln, NE, USA) and incubated with the appropriate primary antibody according 
to the manufacturer's instructions. Antibodies included: anti-IKKa/IKK1 (IMG-
5477, lmgenex, San Diego, CA, USA), IKK~/IKK2 (#2684) , NF-KB2 (p100/p52; 
#4882) , and p-IKBa (#9246) (Cell Signaling Technology, Danvers, MA, USA), 
IKBa (sc-371 ), NF-KB p65 (sc-7151 ), c-Rel (sc-6363) , and NIK (sc-7211) (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA). Anti-GAPDH (G-9545) was used as 
a loading control (Sigma-Aldrich , St. Louis , MO, USA). Alexa Fluor 680 
fluorescent dye-conjugated secondary antibody (Invitrogen) was used for 
visualization with the Li-Cor Odyssey infrared imaging system described 
previously [116]. 
2.10 RNA isolation 
Gastrocnemius and plantaris muscles were harvested from anesthetized 
control and tumor-bearing mice (25 days post-inoculation) , snap-frozen in liquid 
nitrogen, and stored at -80°C until further processing. Total RNA was extracted 
using Trizol reagent (Invitrogen , Carlsbad, CA, USA) according to the 
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manufacturer's instructions. The extracted total RNA was further purified using 
an RNase-Free DNase I kit (Qiagen, Valencia, CA, USA) and an RNeasy Mini kit 
(Qiagen) as previously described [95]. Extracted RNA was quantitated by UV 
spectrophotometry and quality checked by a 1% denaturing agarose gel. 
Samples were also verified by Bioanalyzer 2100 analysis and had a minimal RIN 
number of 8.0 (Agilent, Palo Alto , CA, USA). 
2.11 Microarray analysis 
For microarray analysis, the RNA samples described above were sent to 
the Boston University Medical Center Microarray Core Facility for amplification , 
labeling, and hybridization on a mouse Affymetrix Gene 1.0 ST array (Santa 
Clara, CA, USA) per the manufacturer's instructions to measure the expression 
of 28,132 well-annotated genes. A total of 6 array images (3 control muscle 
samples and 3 C26 muscle samples) were acquired by GeneChip Scanner 3000 
TG and quality assessed by Affymetrix Expression Console (Santa Clara, CA, 
USA). Gene expression signal values were generated by the Expression File 
Creator module of the Gene Pattern platform (Broad Institute, Cambridge, MA) 
and robust multi-array analysis algorithm (RMA) was used for. data preprocessing 
[117]. Brainarray MoGene 1.0 ST custom CDF file v.13 was used for probe 
annotation [118]. Both .ce/ files and expression values were deposited into 
MIAME compliant NCBI Gene Expression Omnibus with accession number: 
GSE48363 
(http://www.ncbi.nlm.nih.gov/geo/querv/acc.cgi?token=rnupvmqqyocggpk&acc=G 
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SE48363). Differential gene expression was computed using the Comparative 
Marker Selection module in GenePattern which compares mean differences 
between control and C26 groups by two-way parametric t-tests. Parameters 
used to identify genes that were differentially expressed in muscle from tumor-
bearing mice were: P-value:::; 0.05, q-value ::5 0.05, and fold change greater than 
1.5-fold. The up- or down-regulated gene lists were uploaded to DAVID 
Bioinformatics database for functional annotation analysis. Biological process 
ontology of the gene list was compared to that of mus musculus genome where 
the threshold of EASE score (a modified Fisher Exact P-value) was set at 0.01 
and a minimum gene count of 2. 
2.12 ChiP-sequencing 
Gastrocnemius and plantaris muscles were isolated from control (i.e., non-
tumor-bearing) and C26 tumor-bearing mice at day 25 post tumor inoculation. 
Freshly dissected muscle was minced and cross-linked in 1% formaldehyde for 
15 min, quenched with glycine and then frozen in liquid nitrogen. For each 
condition (i.e., control or C26) plantar flexor muscle from four legs were pooled, 
homogenized, and chromatin isolated as we detailed previously [95]. This 
material was sonicated to yield chromatin fragments that were on average 250 
bp. An aliquot of sonicated chromatin was put aside to be used as the input 
fraction for ChiP-PCR. The rest of the chromatin was diluted in IP buffer and 
split into a group for incubation with the p65 antibody (Santa Cruz SC-372X) and 
a group without any primary antibody; this was done for chromatin from both 
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control and C26 groups. Samples with and without primary antibody were 
incubated for 16 h at 4 oc with constant low speed mixing and then the antibody-
chromatin complexes were captured with Protein G magnetic beads. The 
chromatin was eluted from the beads and crosslinks reversed , followed by 
pronase/RNase treatment and precipitation of the DNA. One tenth of the 
material was used for PCR for a gene already shown to have robust p65 binding 
in order to test the p65 ChiP. Three different DNA libraries were made: control 
p65 ChiP, C26 p65 ChiP, and ChiP with no primary antibody. The libraries were 
prepared for high throughput sequencing using the lllumina ChiP-seq Library kit. 
An aliquot of each library was examined by acrylamide electrophoresis and Sybr-
gold staining to estimate the quality by size and intensity of the product which 
appears as a smear with an average size of 350 bp. The entire procedure for 
making the three libraries was repeated a second time with new muscle samples 
in order to have two ChiP-seq libraries for each of the three groups. The libraries 
were sent to The Whitehead Institute (Cambridge, MA) where they were cleaned 
of adapter dimers using Ampure XL beads. The cleaned libraries were tested by 
Bioanalyzer and qPCR quality control was performed in order to determine how 
much of each library to use. The libraries were sequenced using Ilium ina Solexa 
sequencing onaGA II sequencer. The resulting sequences from control and 
C26 samples were aligned to the mouse genome (mm9 version) using ELAND. 
The sequences were sent to our lab in the ELAND format. 
The alignments for the two independent control samples were pooled and 
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the same was done for the two C26 samples. In each case this was done by 
combining the .bam forms of the alignments on the Galaxy website. The 
sequences were then evaluated with the FastQC package of quality control tests, 
which was obtained as a standalone program from the Brabaham Institute 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). After the initial 
FastQ analysis two operations were performed on the ChiP-seq data: 1) We 
removed per duplicates using samtools rmdup via Galaxy, and 2) again , using 
samtools, we took advantage of the mapping labels in the ELAND data to isolate 
only reads mapped at unique sites in the mouse genome. Sequence reads were 
35 or 36 base pairs. The three files of ChiP-seq data were: control p65 ChiP 
(1 0.7 million reads) , C26 p65 ChiP (11.1 million reads) , and a file representing 
background sequence reads (8.5 million) obtained by combining control and C26 
sonicated chromatin which was run through the ChiP without a primary antibody 
(no antibody group) . These three post-QC sequence .bam files are available 
online at: 
(https://drive.google.com/folderview?id=OBOPhOYwXvamQektEaTFkcEISL TQ&us 
p=sharing) The aligned sequences were converted to .sam format and then 
uploaded to the peak finder program in Chi Pseeqer [119] with the following 
parameters: 1) threshold= 5, 2) fold change= 2 or greater (compared to 
background) , 3) fragment length= 250 bp, 4) peak length at least 100 bp, and 5) 
peak separation at least 100 base pairs. In addition to identification of control 
and C26 p65 peaks relative to the background (no antibody) , ChiPseeqer 
38 
identified the gene region of the p65 binding peaks (i.e ., genomic location of the 
peaks). 
The sets of control and C26 p65 peaks were run on PeakAnalyzer [120] 
(http://www.ebi.ac.uklresearch/bertone/software#peakanalyzer) in order to find 
the gene with the nearest TSS for each peak. This generates a list of genes with 
peaks less than 1 OOkb from the TSS. The lists were then compared to the lists of 
increased and decreased mRNA expression from the control vs. C26 microarray 
data by using a peri algorithm located on a web page developed by Jim Lund at 
the University of Kentucky (http://nemates.org/MA/progs/Compare.html) . 
Positive Control for ChiP 
To confirm the correct binding of the p65 antibody we used ChiP-PCR to 
examine two NF-KB promoter binding sites in the mouse IP-1 0 (Cxcl1 0) gene that 
have been highly studied and verified [121]. This ChiP experiment also used an 
antibody for p50 (Santa Cruz SC-1190X). A positive control for ChiP was made 
with chromatin from C2C 12 myotubes that had been treated for 4 h with 1 0 ng/ml 
of mouse TN Fa. We previously showed that this treatment strongly induced a 
NF-KB luciferase reporter and increased IP-1 0 mRNA levels, both of which are 
dependent on p65 [51]. For the test experiment we used methods described in 
our previous work [95]. Briefly, formaldehyde fixed chromatin from untreated and 
TNFa-treated C2C12 myotubes was immunoprecipitated with p65 antibody, p50 
antibody, or no antibody and the Protein G-captured precipitates were processed 
to produce DNA which was tested with PCR using primers that flank the two 
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consecutive NF-KB sites in the IP-10 gene. In addition , we also evaluated p65 
and p50 binding to the IP-10 promoter using the chromatin from control and C26 
muscles. 
2.13 Statistics 
An ANOVA or at-test was used for analysis, depending on the number of 
groups being compared. Data are expressed as means± SE, and significance 
was established at P < 0.05. Statistics for microarray data are described in the 
microarray section . 
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Chapter 3 Characterization of Colon 26 tumor-induced cachexia 
3.1 Introduction 
The C26 carcinoma model has been used to study tumor-induced 
cachexia in mice, and we characterized this model by measuring body mass, 
skeletal muscle mass, epididymal fat pad mass, spleen mass, and tumor mass to 
confirm that tumor inoculation induces cachexia in our hands. 
3.2 Results 
3.2.1 Total body mass 
Characterization of this tumor model in our lab involved the inoculation of CDF1 
mice with C26 tumor cells in PBS/matrigel (n=164) or with PBS/matrigel only 
(n=142). Mice were sacrificed at 12, 13, 14, 17, 18, 19, 21 , 22, 23, 24, 25, and 
26 days post tumor cell inoculation. In severe cachexia (days 23-26 post-
inoculation) tumor-bearing mice lost 22.1% ± 0.8% of initial body mass while the 
non-tumor controls gained 12.3% ± 0.7% of initial body mass (Figure 3-1A). 
3.2.2 Skeletal muscle mass 
As tumor mass increased tibialis anterior (TA) muscle mass decreased 
(Figure 3-18) . TheTA muscle mass of severely cachectic mice was 40.4 ± 0.3 
mg compared to 51.1 ± 0.3 mg for age-matched control mice. 
3.2.3 Epididymal fat pad mass 
Tumor-bearing mice in severe cachexia had 214 ± 8.7 mg of epididymal 
fat pad mass while control mice had 465 ± 10 mg (Figure 3-1C). 
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3.2.4 Spleen mass 
The spleen mass of tumor-bearing mice was 205 ± 4.6 mg compared to 
75.5 ± 0.7 mg in non-tumor-bearing mice (Figure 3-10). 
3.2.5 Tumor mass 
Tumor mass increased as a function of time in days post-inoculation 
(Figure 3-1 E). 
3.3 Discussion 
Survivorship appears to vary depending on which clone of C26 is 
inoculated , but most groups reported a mean survival time of 25 days and our 
observations are in agreement with prior studies [8, 54], but one group reported 
limited muscle, fat and total body weight loss even at Day 70 in Clone 5 C26 
tumor-inoculated mice [54]. Another group reported an average survival time of 
45 days in C26 tumor-inoculated mice [122] , so there appear to be C26 clones 
that are less severe in causing cachexia than the one we used. 
Most groups found decreases in total body mass by the third week after 
tumor inoculation, and our findings of 22.1% loss of total body mass were in 
agreement with prior studies [41 , 60, 62-64, 102, 123, 124]. No decreases in 
total body mass were observed in 17-day C26 tumor-bearing mice when the 
tumor was implanted into the liver, but 33% decrease in total body mass was 
reported at Day 17 when the tumor was implanted into muscle [60]. 
Although we and others [52, 64, 1 02] did not find decreases in appetite in 
C26 tumor-bearing animals, some groups did report decreases in food 
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consumption correlated with tumor load. G26 tumor-bearing mice reportedly had 
a 29% decrease in food intake at Day 12 post tumor inoculation [62] and a 72% 
decrease in food intake at Day 17 [63]. 
We found a 20% decrease in skeletal muscle mass and a 35% decrease 
in fiber cross sectional area (GSA) in late-stage G26 tumor-bearing animals, and 
these results are also in agreement with other investigators [8, 25, 41, 62, 64, 
122] though some investigators reported these decreases at much earlier 
timepoints [56] . One group also measured decreases in fiber GSA of fast fiber 
(52% decrease) vs slow fiber (38% decrease) in 3 week G26 tumor-bearing mice 
[125], and these results suggest that slow and fast fiber types atrophy differently 
during G26 tumor-induced cachexia . 
We also found significant to complete depletion of epididymal fat pad 
reserves in G26 tumor-bearing mice, and these results are also in agreement 
with other investigators [52, 54, 60, 102, 122]. 
One group reported significant piloerection at Day 18 post G26 tumor-
inoculation, but we did not observe piloerection in mice inoculated 
subcutaneously. Tumor load was associated with a 3-fold increase in spleen 
mass [8], which we observed , and a 36% increase in liver mass [41], which we 
did not measure. 
Other tumor models such as Lewis lung carcinoma (LLG), Yoshida ascites 
hepatoma, and MAG16 have been used to study tumor-induced cachexia. We 
tried to measure cachexia using the LLG tumor as well (unpublished results), but 
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we found this model to be difficult because tumors were usually on the verge of 
ulceration before any significant atrophy could be measured. We were able to 
induce cachexia much more reliably using the C26 carcinoma. Our findings in 
regard to LLC tumor inoculation are in agreement with another group that 
reported no decreases at all in total body weight in LLC tumor-inoculated animals 
even when the tumor reached a mass of 6 grams [122]. 
Other cachexia-inducing tumors include the Yoshida ascites hepatoma in 
rats and the MAC16 tumor in mice. Rats bearing YAH tumors have rapid onset 
of cachexia only 4-5 days post tumor inoculation [126, 127]. Mice bearing 
MAC 16 tumors also have a rapid onset of cachexia; one group reported a 13% 
decrease in total body mass over a 24-hour period of treatment along with the 
rapid degradation of IKBa, rapid nuclear migration of NF-KB transcription factors, 
a 50% increase in proteolysis rates accompanied by a 50% decrease in protein 
synthesis rates [42]. The rapidity of the development of cachexia suggests that 
these other tumor models are regulated by different signaling pathways than the 
C26 carcinoma. 
The use of different tumor models, inoculation techniques, or end points to 
study tumor-induced cachexia may result in some difficulty in elucidating the 
signaling pathways involved, so care should be taken to avoid generalizations 
from one tumor model to another. Even within the C26 tumor model, some 
groups report significant cachexia as early as Day 12-14 [56, 62, 122], while 
other groups report significant atrophy not developing until Day 22 or Day 24 [41, 
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54, 124]. Some of the differences could be attributed to location of tumor, with 
implantation directly into muscle having a more severe outcome than 
implantation into liver or subcutaneous inoculation. In addition, different signaling 
pathways might regulate cachexia at different stages, so studying the signaling 
proteins and transcription factors at a discrete timepoint may obscure the 
involvement of any one specific signaling pathway in the development of the 
atrophy phenotype. 
45 
A 
140 
:g 120 
"' E 
>-
-g 100 
,Q 
"' E 
.5 80 
~ 0 
0 
c 
800 
~ 
Cl 
E 
-;; 600 
C/) 
"' E 
-of 400 
liS [ 
~ 200 
~ 
c. 
w 
0 
D 
1 2 3 
Tumor mass (g) 
D 
D D 19 
D OJ D CIJ 
• D CtJ 
[]ID D ,P 
D 
• 
•·. Control 
• C26 
4 
Control 
• C26 
D 
B 
60 
Cl 
.§. 
Ill 50 
Ill 
"' E 
~ 40 (.) 
Ill 
::I 
E 
~ 30 
0 
D 
400 
~ 
Cl 
.§. 300 
C/) 
Ill 
liS 
E 200 
1: 
Q) 
Q) 
~ 100 
0 1 
Control 
e C26 
D 
D 't:J D 
D 
2 3 
Tumor mass (g) 
• • 
• 
• 
4 
Control 
• C26 
0~----------~--~~--~~~- 0+-----~----~----r-----~-
0 1 2 3 4 0 2 3 4 
Tumor mass (g) Tumor mass (g) 
E 
• • • 4 
• 
~ 3 C/) 
Ill 
"' E 
0 2 
E 
~ 1 
27 
Days post C26 inoculation 
46 
Figure 3-1. Characterization of cachexia in C26 tumor-bearing mice. (A) 
Body mass change as a function of tumor size. Each value for tumor mice has a 
corresponding value for age-matched control mice. (B) TA muscle mass as a 
function of tumor size. Values for age-matched control mice are plotted for 
comparison. (C) Epididymal fat mass as a function of tumor size. Values for age-
matched control mice are plotted for comparison. (D) The correlation between 
spleen size and tumor mass. (E) Relationship between tumor size and time of 
inoculation. 
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Chapter 4 The role of NF-KB signaling proteins and NF-KB transcription 
factors in muscle wasting in C26 tumor-bearing mice 
4.1 Rationale and aims 
In order to test whether or not the kinase function of IKKa or IKKI3 is 
sufficient to induce skeletal muscle atrophy in mice, constitutively-active forms of 
both IKKa or IKKI3 were overexpressed in mouse tibialis anterior. Fiber cross 
sectional area measurements of transfected fibers compared to non-transfected 
fibers were used as an indicator of skeletal muscle atrophy. In order to 
investigate whether or not the kinase function of IKKa or IKKI3 is required for C26 
tumor-induced skeletal muscle atrophy, dominant-negative forms of IKKa or IKK13 
were overexpressed in the tibialis anterior of both C26 tumor-bearing and non-
tumor-bearing mice. Fiber cross sectional area measurements of transfected 
fibers compared to non-transfected fibers in both C26 tumor-bearing and non-
tumor-bearing mice were used as an indicator of tumor-induced skeletal muscle 
atrophy and inhibition of tumor-induced skeletal muscle atrophy. 
Mutation of IKKI3 (SS177/181EE) mimics phosphorylation at S177 and 
S181 in the catalytic domain and results in a constitutively-active (c.a.) kinase. 
C.a. IKKI3 phosphorylates IKBa at Serines 32 and 36, resulting in the 
ubiquitination and proteasomal degradation of IKBa, and the translocation of 
classical pathway Rei transcription factors to the nucleus. Mutation of IKKa 
(SS 176/180EE) likewise results in a constitutively-active kinase and leads to the 
phosphorylation and processing of p1 00, and the translocation of alternative 
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pathway Rei transcription factors to the nucleus [1 08]. 
In prior work from our lab, overexpression of c. a. IKK~-EGFP in rat soleus 
(slow fiber type) caused 43% atrophy in the fibers expressing the plasmid 
compared to fibers that did not express the plasmid [1 08]. Overexpression of 
c.a . IKKa-EGFP in rat soleus caused 30% atrophy in the fibers expressing the 
plasmid compared to fibers that did not express the plasmid [1 08]. Co-injection 
of both c.a. IKKa and c.a. IKK~ had no additive effect on the atrophy phenotype 
in rats [1 08]. Combined, these data show that IKKa and IKK~ are sufficient to 
induce skeletal muscle atrophy in rat solei , a slow muscle fiber type. 
Transgenic mice overexpressing a muscle-specific c.a . IKK~ (MIKK) had 
normal embryonic muscle development, but post-natally showed a 10- to 13-fold 
increase in IKK~ expression , a 1 0-fold increase in NF-KB binding, and severe 
atrophy in the EDL. EDL mass was 56% lower than controls at 5 weeks of age, 
76% lower than controls at 20 weeks of age, and 86% lower than controls at 35 
weeks of age [98]. This group showed that muscle-specific overexpression of 
IKK~ does not impact embryonic muscle development, but results in a severely 
atrophied post-natal muscle phenotype [98] . 
The aim of the first part of this experiment was to confirm that 
overexpression of c.a . IKKa and c.a . IKK~ were sufficient to induce atrophy in the 
tibialis anterior (TA) muscles (fast fiber type) of wild-type (w.t.) adult mice. I did 
so by injecting c.a. IKKa-EGFP- and c.a. IKK~-EGFP-expressing plasmids into 
theTA muscles of adult, male mice and then comparing cross sectional fiber 
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area measurements of transfected vs. non-transfected fibers. 
The aim of the second part of this experiment was to examine whether 
NF-KB signaling proteins and other NF-KB proteins were required for tumor-
induced skeletal muscle atrophy. Dominant-negative forms of upstream NF-KB 
kinases from both the classical and the alternative NF-KB signaling pathways 
(IKKa, IKK~ , and NIK) were overexpressed in the muscles of tumor-bearing and 
control mice to determine if blocking the upstream kinase activity would have an 
effect on tumor-induced skeletal muscle atrophy. The roles of IKKa and IKKI3, 
were tested by overexpression of dominant-negative forms of these proteins. 
Both d.n. IKKa and d.n. IKKI3 lacked kinase activity due to a lysine-to-methionine 
mutation at residue 44. The role of NIK in the NF-KB alternative pathway was 
tested by overexpression of d.n . NIK, lacking kinase activity due to a lysine-to-
alanine double mutation at residues 429 and 430. The role of IKBa was tested by 
overexpression of a trans-dominant super repressor form of IKBa (IKBaSR), 
which is missing the first 36 amino acids, and is therefore not degradable. 
We also sought to determine if the NF-KB transcription factors ReiA (p65) 
or c-Rel were required for tumor-induced muscle wasting by overexpressing d.n. 
p65 or d.n. c-Rel, respectively. Both dominant-negative forms of the transcription 
factors were truncated proteins, missing both C-terminal transactivation domains. 
Because the Rei homology domain (RHO) was intact in both ReiA and c-Rel, the 
dominant-negative transcription factors still retained the ability to dimerize, 
translocate to the nucleus and bind DNA, but were unable to activate 
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transcription (Figure 51). We measured fiber cross sectional area in transfected 
and non-transfected fibers to determine if atrophy would be attenuated in fibers 
transfected with these dominant-negative signaling proteins or dominant-negative 
transcription factors. 
NF-KB transcription factor binding to an NF-KB oligonucleotide and NF-KB 
transcriptional activity of a reporter were measured to assess whether NF-KB-
dependent transcription was increased in muscles of tumor bearing mice. To 
determine if p65, the canonical NF-KB transcription factor, bound target genes 
that could be related to atrophy regulation, we performed ChiP-sequencing in 
muscle from control and tumor-bearing mice in conjunction with measurement of 
global gene expression as a functional measure of cachexia-induced changes in 
gene expression. 
The intracellular signaling pathways and transcriptional regulation of muscle 
wasting due to cancer are just beginning to be understood. The purpose of this 
study was to identify NF-KB signaling proteins, NF-KB transcription factors, and 
NF-KB transcription factor target genes in cancer-induced muscle wasting. The 
existing literature indicates the involvement of the NF-KB signaling protein , IKBa, 
because LLC tumor-bearing mice overexpressing a super repressor form of IKBa 
in skeletal muscle showed a 50% inhibition of muscle fiber atrophy. In that study, 
increased binding of the p65 NF-KB transcription factor was found in muscle from 
mice with tumors and this was reversed in the presence of overexpressed 
IKBaSR [98]. There was also some evidence that NF-KB transcription was 
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activated in C26 mouse colon carcinoma [9]. Therefore, we performed in-depth 
studies to determine the requirement of the major known NF-KB signaling 
proteins and the NF-KB transcription factors in cancer-induced muscle wasting. 
4.2 Results 
4.2.1 Overexpression of c.a. IKKa-EGFP and c.a. IKKJ3-EGFP 
C.a. IKKa-EGFP-expressing fibers were 79.6% of fibers not expressing 
c.a. IKKa-EGFP. Therefore, overexpression of c.a. IKKa-EGFP resulted in 
20.4% muscle atrophy as measured by fiber cross sectional area (Figure 4-1A) . 
C.a. IKKf3-EGFP-expressing fibers were 78.2% of fibers not expressing c. a. 
IKKf3-EGFP. Therefore, overexpression of c.a . IKKf3-EGFP resulted in 21.8% 
muscle atrophy as measured by fiber cross sectional atrophy (Figure 4-1A) . An 
example of a muscle cross section used for measurement of fiber area is shown 
(Figure 4-1 B). 
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Figure 4-1. Effects of c.a. IKKa-EGFP or c.a. IKK~-EGFP on muscle fiber 
cross sectional area (CSA). A) Mean tibialis anterior (TA) fiber cross-sectional 
area in control mice in the presence or absence of c.a. IKKa-EGFP or c. a. IKKI3-
EGFP. Each bar represents mean fiber area from 2 muscles(± SE). B) 
Representative cross section of TA muscle from mice injected with the c.a. IKK13-
EGFP plasmid. 
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4.2.2 Overexpression of d.n. IKK(3-EGFP 
The mean fiber cross sectional area from TA muscles of C26 tumor-
bearing mice was 35.3% less than fibers from non-tumor-bearing control mice 
(Figure 4-2A). However, overexpression of d.n. IKK~-EGFP blocked fiber 
atrophy by 69%. Plotting the individual fiber areas from muscles in each group 
by size vs. frequency reveals the heterogeneous distribution of muscle fiber area 
and shows the leftward shift to smaller fiber size due to cancer and the blocking 
of that shift in fiber size in the same muscles overexpressing d.n. IKK~-EGFP 
(Figure 4-28). Confirmation of expression of full-length d.n. IKK~-EGFP is 
illustrated by western blot (Figure 4-2C), and examples of muscle sections used 
for measurement of fiber area are shown (Figure 4-20). 
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Figure 4-2. Effects of d.n. IKKJ3-EGFP on muscle fiber cross sectional area 
(CSA). (A) Mean tibialis anterior (TA) fiber cross-sectional area in control and 
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C26 tumor-bearing mice in the presence or absence of d.n. IKK~-EGFP . Each 
bar represents mean fiber area from 8 muscles. Overexpression of d.n. IKK~­
EGFP blocked fiber atrophy by 69% (± SE). The average number of fibers 
measured per muscle was 200. (B) Fiber area frequency distribution of all fibers 
from muscles of control, C26, and C26 + d.n. IKK~-EGFP groups. (C) Western 
blots of lysates from TA muscles injected with the empty vector (EV) or d.n. 
IKK~-EGFP plasmid confirms overexpression of the fusion protein. d.n. IKK~­
EGFP is 114 kDa. All samples are from the same immunoblot. (D) 
Representative cross sections of TA muscles from control and C26 tumor-
bearing mice injected with the d.n. IKK~-EGFP plasmid. Fluorescent red 
represents laminin staining (anti-laminin incubation followed by Texas Red-X 
fluorescent dye-conjugated secondary antibody). Fluorescent green cytoplasm 
represents expression of transfected d.n. IKK~-EGFP. C =control; * significantly 
different from control (P<0.05). t significantly different from C26 fibers not 
transfected with d.n. IKK~-EGFP (P<0.05). 
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4.2.3 Overexpression of IKBaSR-EGFP 
The mean fiber cross sectional area from TA muscles of C26 tumor-
bearing mice was 42.3% less than fibers from non-tumor-bearing control mice. 
However, overexpression of IKBaSR-EGFP blocked C26 tumor-induced fiber 
atrophy by 41.4% (Figure 4-3A). Plotting the individual fiber areas from muscles 
in each group by size vs . frequency reveals the heterogeneous distribution of 
muscle fiber area and shows the leftward shift to smaller fiber size due to cancer, 
and the blocking of that shift in fiber size in the same muscles overexpressing 
IKBaSR-EGFP (Figure 4-38). Confirmation of the overexpression of full length 
IKBaSR-EGFP is shown by western blot (Figure 4-3C) and examples of muscle 
sections used for measurement of fiber area are shown (Figure 4-30) . 
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Figure 4-3. Effects of IKBaSR-EGFP on muscle fiber cross sectional area 
(CSA). (A) Mean tibialis anterior (TA) fiber cross-sectional area in control and 
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C26 tumor-bearing mice in the presence or absence of IKBaSR-EGFP. Each bar 
represents mean fiber area from 8 muscles. The average number of fibers 
measured per muscle was 200. Overexpression of IKBaSR-EGFP blocked C26 
tumor-induced fiber atrophy by 41.4% (± SE). (B) Fiber area frequency 
distribution of all fibers from muscles of control, C26, and C26 + IKBaSR-EGFP 
groups. (C) Western blots of lysates from TA muscles injected with the empty 
vector (EV) or IKBaSR-EGFP plasmid confirms overexpression of the fusion 
protein. IKBaSR-EGFP is 64 kDa. All samples are from the same immunoblot. 
(D) Representative cross sections of TA muscles from control and C26 tumor-
bearing mice injected with the IKBaSR-EGFP plasmid. C =control. *significantly 
different from control (P<0.05). t significantly different from C26 fibers not 
transfected with IKBaSR-EGFP (P<0.05). 
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4.2.4 Overexpression of d.n. IKKa-EGFP 
The mean fiber cross sectional area from TA muscles of C26 tumor-
bearing mice was 28.2% less than fibers from non-tumor-bearing control mice 
(Figure 4-4A). Overexpression of d.n. IKKa-EGFP did not block C26 tumor-
induced fiber cross sectional area atrophy (Figure 4-4A) . Plotting the individual 
fiber areas from muscles in each group by size vs frequency reveals the 
heterogeneous distribution of muscle fiber area and shows the leftward shift to 
smaller fiber size due to cancer and no blocking of that shift in fiber size in the 
same muscles overexpressing d.n. IKKa-EGFP (Figure 4-48). We have 
previously shown that overexpression of EGFP alone does not affect fiber area 
[94]. Confirmation of the overexpression of full length d.n. IKKa-EGFP is shown 
by western blot (Figure 4-4C) and examples of muscle cross-sections used for 
measurement of fiber area are shown (Figure 4-40) . 
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Figure 4-4. Effects of d.n. IKKa-EGFP on muscle fiber cross sectional area 
(CSA). (A) Mean tibialis anterior (TA) fiber cross-sectional area in control and 
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C26 tumor-bearing mice in the presence or absence of. Each bar represents 
mean fiber area from 8 muscles(± SE). Overexpression of d.n. IKKa-EGFP did 
not block C26 tumor-induced fiber cross sectional area atrophy. The average 
number of fibers measured per muscle was 200. (B) Fiber area frequency 
distribution of all fibers from muscles of control , C26, and C26 + d.n. IKKa-EGFP 
groups. (C) Western blots of lysates from TA muscles injected with the empty 
vector (EV) or d.n. IKKa-EGFP plasmid confirms overexpression of the fusion 
protein. d.n. IKKa-EGFP is 108 kDa. All samples are from the same 
immunoblot. (D) Representative cross sections ofT A muscles from control and 
C26 tumor-bearing mice injected with the d.n. IKKa-EGFP plasmid. C =control. 
*significantly different from control (P<0.05). 
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(A} Mean tibialis anterior ( I A) t1ber cross-sectional area in control and C26 
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tumor-bearing mice in the presence or absence of d.n. NIK. Each bar represents 
mean fiber area from 8 muscles (± SE). The average number of fibers measured 
per muscle was 200. Overexpression of d.n. NIK-GFP did not block C26 tumor-
induced fiber cross sectional area atrophy. (B) Fiber area frequency distribution 
of all fibers from muscles of control, C26, and C26 + d.n. NIK groups. (C) 
Western blots of lysates from TA muscles injected with the empty vector (EV) or 
d.n . NIK plasmid confirms overexpression of the protein. d.n. NIK = 130 kDa. All 
samples are from the same immunoblot. (D) Representative cross sections of 
TA muscles from control and C26 tumor-bearing mice injected with the d.n . NIK 
plasmid (encodes GFP on separate cistron) . C =control. *significantly different 
from control (P<0.05) . 
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4.2.6 Overexpression of d.n. p65-EGFP 
The mean fiber cross sectional area from TA muscles of C26 tumor-
bearing mice was 41.3% less than fibers from non-tumor-bearing control mice. 
Overexpression of d.n. p65-EGFP reversed C26-induced fiber atrophy by only 
20.8% (Figure 4-6A). Plotting the individual fiber areas from muscles in each 
group by size vs. frequency reveals the heterogeneous distribution of muscle 
fiber area and shows the leftward shift to smaller fiber size due to cancer and the 
slight blocking of that shift in fiber size in the same muscles overexpressing d:n. 
p65-EGFP (Figure 4-68). Confirmation of the overexpression of full length d.n. 
p65-EGFP is shown by western blot (Figure 4-6C). The d.n. p65 is a truncated 
protein , containing a.a. 1-313 and missing the transactivation domains on the C-
terminus. However, fusion of d.n . p65 to EGFP makes the fusion protein 
approximately the same size as endogenous p65 (Figure 4-60). Figure 4-6E 
shows representative muscle cross-sections from which fiber area was 
measured. 
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Figure 4-6. Effects of d.n. p65-EGFP on muscle fiber cross sectional area 
(CSA). (A) Mean tibialis anterior (TA) fiber cross-sectional area in control and 
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C26 tumor-bearing mice in the presence or absence of d.n. p65-EGFP. Each bar 
represents mean fiber area from 8 muscles. The average number of fibers 
measured per muscle was 200. Overexpression of d.n. p65-EGFP blocked C26 
tumor-induced fiber cross sectional atrophy by 20.8% (± SE). (B) Fiber area 
frequency distribution of all fibers from muscles of control, C26, and C26 + d.n. 
p65-EGFP groups. (C) Western blots of lysates from TA muscles injected with 
the empty vector (EV) or d.n. p65-EGFP plasmid confirms overexpression of the 
fusion protein. (D) The d.n. p65(313)-EGFP fusion protein (313 a.a.+ 238 a.a. = 
551 a.a. = 63kDa) is of similar molecular weight as endogenous mouse whole 
p65 protein (549 a.a. = 60.2kDa) and they are not separable on a 4-15% gradient 
polyacrylamide gel. All samples are from the same immunoblot. (E) 
Representative cross sections of TA muscles from control and C26 tumor-
bearing mice injected with the d.n. p65-EGFP plasmid. C =control. *significantly 
different from control (P<0.05). t significantly different from C26 fibers not 
transfected with d.n. p65-EGFP (P<0.05). 
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4.2.7 Overexpression of d.n. c-Rei-EGFP 
The mean fiber cross sectional area from TA muscles of C26 tumor-
bearing mice was 31.4% less than fibers from non-tumor-bearing control mice. 
Overexpression of d.n. c-Rei-EGFP did not affect fiber atrophy (Figure 4-7 A). 
Plotting the individual fiber areas from muscles in each group by size vs. 
frequency reveals the heterogeneous distribution of muscle fiber area and shows 
the leftward shift to smaller fiber size due to cancer and no blocking of that shift 
in fiber size in the same muscles overexpressing d.n. c-Rei-EGFP (Figure 4-78). 
Confirmation of the overexpression of full length d.n. c-Rei-EGFP is shown by 
western blot (Figure 4-7C). Examples of muscle sections used for measurement 
of fiber area are shown (Figure 4-70). 
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Figure 4-7. Effects of d.n. c-Rei-EGFP on muscle fiber cross sectional area 
(CSA). (A) Mean tibialis anterior (TA) fiber cross-sectional area in control and 
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C26 tumor-bearing mice in the presence or absence of d.n. c-Rei-EGFP. Each 
bar represents mean fiber area from 8 muscles (± SE). The average number of 
fibers measured per muscle was 200. Overexpression of d.n. c-Rei-EGFP did 
not block C26 tumor-induced fiber cross sectional area atrophy. (B) Fiber area 
frequency distribution of all fibers from muscles of control, C26, and C26 + d.n . c-
Rei-EGFP groups. (C) Western blots of lysates from TA muscles injected with 
the empty vector (EV) or d.n . c-Rei-EGFP plasmid confirms overexpression of 
the fusion protein. d.n. c-Rei-EGFP is 60 kDa. All samples are from the same 
immunoblot. (D) Representative cross sections of TA muscles from control and 
C26 tumor-bearing mice injected with the d.n. c-Rei-EGFP plasmid . C =control. 
*significantly different from control (P<0.05). 
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4.3 NF-KB transcription factor binding to a NF-KB oligonucleotide 
electrophoretic mobility shift assay (EMSA) 
EMSAs were performed using gastrocnemius muscle nuclear extracts 
isolated from tumor-bearing mice (13 to 23-days post-inoculation) and from age-
matched controls (12 control muscles and 14 C26-inoculated muscles) as 
another way to assess NF-KB transcription factor activity in C26 tumor-induced 
cachexia. Figure 4-8A shows representative examples of NF-KB oligonucleotide 
binding from control and C26 extracts isolated at 23 days post-tumor cell 
inoculation. The specificity of protein-DNA binding was determined by addition of 
excess unlabeled consensus NF-KB oligonucleotide competitor to binding 
reaction. There was no significant difference in the amount of protein binding 
due to the tumor regardless of the number of days after tumor cell inoculation. 
Measurement of band intensity was combined for each time point and mean 
values were plotted for control vs. C26 mice (Figure 4-88). 
As a positive control for our method of nuclear extract isolation and NF-KB 
gel shift procedures we performed an EMSA using muscle extracts from control 
and laminin-alpha2 deficient mice (muscles from M. Girgenrath). These muscles 
are characterized by inflammatory markers including significant mononuclear 
infiltration [128] and accordingly we show significant increases in protein binding 
(Figure 4-8C) to the same NF-KB oligonucleotide used for control vs. cancer 
mice. 
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Figure 4-8. Gel shift assay of NF-KB binding and positive control. (A) Bands 
represent protein-oligonucleotide binding of gastrocnemius nuclear extracts from 
control and C26 mice 23 days post-inoculation. 20 j..Jg of protein incubated with 
infrared dye labeled NF-KB oligonucleotide. A lane labeled "Cold" indicates 
incubation with 200X unlabeled consensus oligonucleotide competitor. 
Competitor lane was on same gel as lanes 1 through 4. (B) Signal intensity of 
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bands representing protein binding to NF-KB oligonucleotide; control mean value 
represents 12 independent samples, C26 mean value represents 14 independent 
samples. Values were combined from 13, 17 and 23 days post-tumor cell 
inoculation since there was no difference in binding compared to controls at any 
time point. (C) As a positive control for the NF-KB EMSA, nuclear extracts 
isolated from hind-limb muscles of 42 day old Lamaz1- mice compared to aged-
matched C57BL/6 wild type (WT) controls are shown. 15 !Jg of protein incubated 
with infrared dye labeled NF-KB oligonucleotide. + indicates incubation with 150X 
unlabeled consensus oligonucleotide competitor. Each lane represents an 
independent muscle sample. 
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4.4 NF-KB-dependent reporter activity in muscles from control vs. C26 
tumor-bearing mice 
Another assay to determine if NF-KB transcriptional activity was elevated in 
muscles from tumor bearing mice was measurement of the activity of a NF-KB 
dependent luciferase reporter plasmid injected into the T A muscle of control and 
C26 mice. Two time points post-inoculation were assessed which represented 
mild and severe cachexia (12 and 25 days). NF-KB reporter activity in theTA 
muscle was not different at either 12 or 25 days indicating that protein binding 
and/or post-translational changes to protein binding of the reporter gene did not 
increase NF-KB transcriptional activity in cachexia (Figure 4-9). We have shown 
that this same NF-KB reporter plasmid is strongly activated in mouse hind limb 
muscle due to unloading [91, 94] and in cultured mouse myotubes due to 
treatment with TNFa, IL-113, IL-1a, or TWEAK [51, 129]. These results showing 
no activation of the NF-KB reporter in muscles of mice with C26 tumors are 
consistent with the electrophoretic mobility shift assay results. 
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Figure 4-9. NF-KB-dependent reporter activity in TA muscles from control 
and C26 tumor-bearing mice. NF-KB-dependent luciferase activity in TA 
muscles at 12 and 25 days after tumor cell inoculation representing mild and 
severe cachexia. The number of muscles per group was 6 for the 12-day time 
point and 8 for the 25-day time point. 
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4.5 Expression of p100/p52 in muscles from control vs. C26 tumor-bearing 
mice 
When the alternative NF-KB signaling pathway is activated, p1 00 is 
phosphorylated, ubiquitinated, and post-translationally processed to the p52 NF-
KB transcription factor. The post-translationally processed p52 is the active form, 
and it is known to dimerize with ReiB, translocate to the nucleus, and bind DNA 
to upregulate NF-KB-dependent alternative pathway genes. Post-translational 
processing can be used as an indirect measure of alternative pathway activation . 
We measured protein levels of p1 00 and p52 in muscle homogenates from 
control and C26 tumor-bearing mice in order to assess signaling activity of the 
alternative pathway. Western blot showed no change in the amount of p1 00 or 
p52 protein in muscles from control vs . C26 mice 21 days after tumor cell 
inoculation (Figure 4-1 0). This is consistent with the lack of effect on cachexia 
with overexpression of d.n. NIK and d.n. IKKa which are upstream kinases of the 
alternative NF-KB pathway. 
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Figure 4-10. Western blot of p100 and p52 from TA muscle of control and 
C26 tumor-bearing mice. Muscles were from mice 21 days post C26 
inoculation. 70 1-19 of lysate loaded per lane. Blot incubated with p1 OO/p52 (NF-
KB2) antibody. Each lane represents an independent muscle sample. Whole cell 
extract from 5 min TN F-a-treated Hela cells were used as positive control. 
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4.6 Genome-wide mRNA expression microarray 
Whole-transcript gene expression arrays were used for mRNA expression 
profiling of muscles to compare with ChiP-seq data and to verify gene expression 
changes in our hands. Among 28,000 transcripts investigated at day 25 post 
tumor inoculation, 1,907 genes were differentially expressed in muscles from 
tumor bearing mice using q:50.05 and fold change ~1.5; 1034 genes were 
upregulated and 873 genes were down-regulated (Table 51) . Differentially 
expressed genes in muscle from tumor bearing mice were similar to those 
previously published in severe C26 cancer cachexia [41] such as upregulation of 
acute phase response genes, ubiquitin-proteasomal degradation genes, 
autophagy genes, key atrophy genes including MuRF1, atrogin/MAFbx, 
cathepsin L, caspase4, Foxo1, Foxo3, Stat3, Socs3, C/EBPo, Bcl-3, myogenin , 
Jun B, etc. Selected transcripts that were upregulated by 1.5-fold or greater are 
listed for several relevant functional categories; this includes genes involved in 
ubiquitin-proteosomal protein degradation, autophagy, other proteolytic 
processes, and immune function (Figure 4-11) . To identify the computationally 
derived functional processes from the 1,907 differentially expressed genes, we 
used DAVID's Functional Annotation analysis (Table 52). For upregulated 
genes, 22 GO terms (biological process) were significantly enriched; 9 were 
associated with proteolysis or catabolic processes, 4 were related to 
inflammatory processes, and 3 were associated with translation. The genes 
found for these GO categories are contained in the selected upregulated genes 
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shown in the heatmap (Figure 4-11 ). For downregulated genes, 8 GO terms 
were enriched; these processes were oxidation reduction, generation of 
precursor metabolites and energy, extracellular structure organization, 
extracellular matrix organization, striated muscle tissue development, muscle 
tissue development, electron transport chain, and collagen fibril organization. 
The list of up- and down-regulated genes belonging to the DAVID-identified GO 
categories are listed in Table 52. Table 53 shows the fold changes and p-
values for the up-regulated genes depicted in the heat map, as well as the fold 
changes and p-values for down-regulated genes identified by DAVID analysis for 
the categories of extracellular matrix organization, striated muscle tissue 
development, muscle tissue development, and collagen fibril organization. 
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Figure 4-11. Heatmaps of selected upregulated genes in plantar flexor 
muscles from several functional categories . Data are from muscles at 25 
days post-tumor inoculation (severe cachexia). Red color in the heatmap 
represents gene upregulation in muscles from C26 mice compared to the lower 
control values represented by blue. All genes represented are increased greater 
than 1.5-fold. Genes involved in : ubiquitin-proteasomal protein degradation, 
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• 
autophagy, other proteolytic processes (e.g . caspases, cathepsins, and 
metalloproteases), immune responses (innate and adaptive) , and transcription 
factor genes are shown. The heatmaps capture most of the upregulated genes 
in these functional categories but do not represent a complete list (see Table S2). 
Each color block represents one pooled sample (control n=3; C26 n=3). Some of 
the genes were verified by qPCR. Mean fold change values for these genes are 
listed in Table 53. 
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4. 7 ChiP-Seq of p65 in muscle from control vs. C26 tumor-bearing mice 
p65 carries the transactivation domain for itself and for p50 in the classical 
heterodimer of NF-KB and so its binding in ChiP is referred to "as the hallmark of 
the active NF-KB complex" [130]. We tested our p65 antibody, already validated 
in the literature [95, 131], for use in our p65 ChiP sequencing libraries by testing 
it on a bona fide KB site cluster (two sites separated by 46 nucleotides) in the IP-
10 gene. We prepared untreated or TNFa-treated C2C12 myotube 
formaldehyde-fixed chromatin and performed ChiP using no antibody, p65 
antibody, or p50 antibody. Binding was evaluated by PCR using primers flanking 
the highly conserved verified NF-KB sites in the IP-10 gene promoter. The 
results showed marked increases in the PCR product representing p65 and p50 
binding due to TNFa treatment (Figure 4-12A, 4-128). 
We then performed ChiP from control and C26 muscles, using our tested 
p65 antibody and sequenced the resulting DNA libraries. We used the quality 
control analyses of FastQC (Figures 53-5) to confirm that our libraries consisted 
of high quality uniquely mapped sequences on the mouse genome without 
redundancies due to the PCR used in amplification. This generated 11.1 x 106 
and 10.8 x 1 06 unique alignments for cancer and control sequences, 
respectively, on the mouse genome. ChiPseeqer was used, set to the same 
threshold that we had employed for Bcl-3 binding to unloaded muscle chromatin 
[93], and peaks were identified from the p65 antibody-captured alignments in 
control and C26 muscles. Allowing each peak to be a maximum of 1 OOkb from 
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its nearest gene TSS, there were only 1 00 peaks in the controls and 57 peaks in 
the C26 samples. The genes associated with these peaks are presented in 
Table 54. 
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Figure 4-12. ChiP PCR to validate the p65 antibody and comparison of p65 
binding in cancer cachexia vs. a classic inflammatory system. (A) 
Chromatin was prepared from C2C12 myotubes that had been untreated or 
treated with 10 ng/ml mouse TNF for 4 hours and from (B) 
gastrocnemius/plantaris muscles of mice with and without 25 days of C26 tumor-
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induced cachexia. Chromatin was sonicated and immunoprecipitated without 
antibody or with the same antibody to p65 used for ChiP-seq or with a p50 
antibody. Captured precipitates were used to prepare DNA template evaluated 
by PCR with primers that flank two closely spaced validated NF-KB sites in the 
IP-1 0 promoter. PCR products are shown on acrylamide gels, stained with Sybr 
gold. Standards are 100 bp ladder. Input lanes are PCR products using the same 
primers on chromatin taken before ChiP. 
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4.8 Discussion 
Overexpression of the c. a. forms of IKKa and IKKI3 showed that both 
kinases are sufficient to induce significant skeletal muscle atrophy in mouse TA 
muscle. These results are in agreement with prior work from our lab using rat 
soleus [1 08] , as well as with studies using MIKK transgenic mice (overexpressing 
a muscle-specific c.a. IKKI3) [98] . 
Blocking the activity of NF-KB signaling proteins by overexpression of 
dominant-negative or transdominant forms of the signaling proteins showed that 
the kinase activity of IKKI3 and the degradation of IKBa were required for C26 
tumor-induced atrophy, but the kinase activity of IKKa and NIK were not required 
for tumor:-induced skeletal muscle atrophy. Blocking the transactivation function 
of two NF-KB transcription factors , p65 (ReiA) and c-Rel showed that these 
transcription factors are not key regulators of C26 tumor-induced skeletal muscle 
atrophy. 
This is the first in-depth study on the role of NF-KB signaling and of NF-KB 
transcription factors in the regulation of muscle wasting due to cancer. The 
robust 69% inhibition of C26-induced muscle wasting when d.n . IKKI3 is 
overexpressed demonstrates a requirement for IKK13 in C26-induced muscle 
wasting . We also confirmed that IKBa is involved in C26-induced wasting as 
previously described for LLC-induced wasting [98]. Surprisingly, neither p65 nor 
c-Rel was required for C26 atrophy since overexpression of dominant-negative 
forms of these proteins did not affect fiber size significantly. Although knockout 
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mice for p50 (NF-KB1/p1 05) and Bcl-3 were used to show that those classical 
NF-KB transcription factors were required for hindlimb unloading-induced atrophy 
[91 ), we were unable to use these knockout mice to study the possible 
involvement of p50 and Bcl-3 in C26 tumor-induced atrophy because the 
background strain used for the deletion mutants is not compatible with the C26 
tumor cell line. 
IKKa and NIK were not necessary for muscle wasting indicating that the 
alternative NF-KB signaling pathway is not involved in the atrophy process. This 
was further confirmed by western blots showing no change in the expression of 
p52 NF-KB transcription factor or its precursor protein, p1 00, in cachexia . 
Classical and alternative NF-KB signaling pathways have been shown to have 
divergent roles in muscle in response to cytokine mediated atrophy and during 
muscle development [82, 114, 132, 133], however since we found evidence for 
IKKI3, and not alternative NF-KB signaling in C26 cachexia , those divergent 
actions do not appear to function here. 
Gel shift assays showed no change in nuclear protein binding to NF-KB 
oligonucleotides and there was no change in NF-KB-dependent reporter activity 
in muscles of control vs. C26 tumor bearing mice. Importantly, using genome-
wide ChiP-sequencing , we found almost no NF-KB p65 binding peaks in genes 
shown to be upregulated in cancer cachexia as assessed by our gene 
expression microarrays, so the upregulations of atrophy genes or cytokine genes 
are not mediated by p65, as assessed by ChiP-seq . 
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4.9 Conclusions 
We demonstrated that inhibition of NF-KB signaling proteins, IKKI3 and 
IKBa significantly inhibited C26 tumor-induced atrophy by 69% and 41%, 
respectively. However, the inhibition of NF-KB alternative pathway signaling 
proteins had no effect on C26 tumor-induced atrophy. The inhibition of the two 
NF-KB classical pathway transcription factors containing transactivation domains, 
Re1A/p65 and c-Rel, had no major effect on C26 tumor-induced atrophy. 
Therefore, C26 tumor-induced atrophy appears to be regulated by IKK13-
dependent, but NF-KB transcription factor independent signaling. 
The inhibition of IKKI3 inhibits unloading-induced atrophy in rat soleus 
[1 08] and denervation-induced atrophy in rat soleus [134], but NF-KB-dependent 
luciferase reporter activity increased in unloaded rat muscles, and the inhibition 
of IKKI3 kinase activity partially blocked the increase in NF-KB-dependent 
luciferase reporter activity [1 08]. The inhibition of IKBa also attenuated muscle 
atrophy in mice overexpressing c.a. IKKI3 [98], in hindlimb unloaded rats and 
mice [94], in denervated mice [98], in mice sustaining LPS-acute pulmonary 
injury [135], and in LLC tumor-bearing mice [98]. Again , unloading induced an 
increase in NF-KB-dependent luciferase reporter activity which was completely 
abolished in the presence of the IKBa-SR [94]. These results show that 
unloading-induced atrophy is regulated by both NF-KB signaling proteins and 
transcription factors, unlike C26 tumor-induced atrophy. 
Other studies support the finding that tumor-induced cachexia may be 
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IKK-dependent but NF-KB-independent. For instance, NF-KB transcription factor 
levels were not elevated in theTAs of cachectic LLC tumor-bearing mice or 
Yoshida ascites hepatoma tumor-bearing rats [142]. Treatment with curcumin to 
block phosphorylation of IKBa did not attenuate muscle wasting in Yoshida 
ascites hepatoma tumor-bearing rats though it did decrease tumor growth by 
31% [142]. EMSA on nuclear extracts from muscle showed no increase in NF-KB 
binding activity in rats with Yoshida ascites hepatoma [48]. Two groups found 
only small increases in NF-KB binding [9, 1 02] and one group reported that this 
signaling was not responsible for the upregulated atrophy genes [9]. It is likely 
the case that different tumors induce cachexia through different signaling 
pathways. 
One group reported an increase in p65 binding activity in LLC tumor-
bearing mice suggesting that classical NF-KB transcription factors play a role in 
LLC tumor-induced cachexia [98], but we did not find p65 or c-Rel to be 
important for C26 tumor-induced atrophy. The requirement for the NF-KB 
signaling protein IKK~, but not the NF-KB transcription factors suggests that 
inhibition of IKK~ is blocking other cellular processes requiring this kinase that in 
turn regulate muscle wasting via transcription factors other than the NF-KB family 
members. As further evidence that IKK~ is not phosphorylating IKBa, levels of 
endogenous IKBa and IKBa phosphorylation are unchanged at either 10 or 24 
days after tumor inoculation (Figure 52). The process of muscle wasting due to 
C26 cancer may be another example of IKK~ signaling that is independent of NF-
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KB transcription. 
In order to examine the intracellular signaling pathways leading to C26 
tumor-induced cachexia in a more simplified system, we transfected C2C12 
murine myotubes with the same NF-KB classical pathway, dominant-negative 
signaling proteins used in the in vivo studies. We induced myotube atrophy by 
treating C2C12 murine myotubes with C26 cancer cell-conditioned medium. 
Then we assessed myotube atrophy by measuring myotube diameters. We were 
able to recapitulate the C26 conditioned medium-induced atrophy in C2C12 
myotubes reported by Lokireddy et al. 2012 [29]. We found a 20% decrease in 
myotube diameter in 3-day differentiated C2C12 myotubes after 24 hours of C26 
conditioned medium treatment (Figure 56). The C26 conditioned medium-
induced decrease in myotube diameter was completely blocked in myotubes 
transfected with d.n . IKK~-EGFP (Figure 57) and in myotubes transfected with 
the IKBa-SR-EGFP (Figure 58). Chemical inhibition of p65 via the toxin 
helenalin did not significantly inhibit conditioned medium-induced myotube 
atrophy (Figure 59) . In addition , myotubes treated with C26 conditioned medium 
and transfected with an NF-KB-dependent luciferase reporter showed no 
increase in NF-KB transcription factor binding compared to untreated control 
myotubes (Figure 51 0). These in vitro experimental results match our in vivo 
tumor studies, so we may be able to identify promising avenues for in vivo work 
using this more easily manipulated cell culture model. 
The possibility that the IKKs may be activated while not activating NF-KB-
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regulated transcription has been demonstrated multiple times over the past 
decade [136-141]. This has been referred to as IKK-dependent, NF-KB-
independent signaling [137] . We recently reviewed IKK-dependent, NF-KB-
independent literature in detail [143]. IKK substrates other than IKBa have been 
identified, and IKBa substrates other than the Rei transcription factors have also 
been identified [136]. Future attention should be directed toward IKKI3-kinase 
targets that are NF-KB-independent such as TSC-1, ERK1/2, p53, lysosomal 
proteins [143], ATG-5, BEC-1 [137,141], CARMA1 , CYLD, IRS-1, Dok1 , 14-3-3~ . 
Aurora A, and SNAP23 [83]. Of these known IKKI3-dependent, NF-KB-
independent substrates, a few are promising candidates for further investigation 
for possible roles in C26 tumor-induced cachexia. 
The autophagy-associated genes ATG-5 and Beclin-1 may play a role in 
tumor-induced wasting. These two autophagy genes are known IKKI3 targets , 
and there is evidence to support autophagy as a proteolytic pathway during 
tumor-induced cachexia. Our in vivo microarray results revealed mRNA 
upregulation of a group of autophagy-related genes including Ctsl, Bnip3 and 
Gabarap (see Figure 4-11). In addition, the microarray results from C2C12 
myotubes treated with C26 conditioned med ium revealed a 12.07-fold increase in 
ATG-5 mRNA levels compared to untreated cells [29]. Increased mRNA levels of 
cathepsins in human lung cancer patients, C26 carcinoma, Yoshida ascites 
hepatoma, and Lewis lung carcinoma [1, 2, 27, 28, 30] suggest that tumor-
induced proteolysis could occur by pathways other than the ubiquitin-proteasome 
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degradation. In knockout cell culture studies, the NF-KB signaling proteins (IKKI3 
and IKBa) are required for serum deprivation-induced autophagy, but not IKKa, 
p65, c-Rel, ReiB, or p52 [137, 141]. Therefore, while IKKI3 activity is required for 
starvation-induced autophagy, the activity of the NF-KB transcription factors is 
dispensable [137, 141]. The requirement for IKKI3, but not NF-KB transcription 
factors, suggests that inhibition of IKKI3 is blocking other cellular processes 
requiring this kinase that in turn regulate muscle wasting via transcription factors 
other than the five mammalian NF-KB family members. The mechanism by 
which IKKI3 promotes autophagy during serum deprivation in MEFs is not known. 
As with C26 tumor-induced cachexia, further work is needed to elucidate this 
IKKI3-dependent, NF-KB-independent signaling pathway. 
IKKI3 has NF-KB-independent kinase activity on other substrates as well 
[143]. For instance, the IKK13-mediated phosphorylation of tumor suppressor 
complex (TSC-1) suppresses its activity and activates vascular endothelial 
growth factor (VEGF) to stimulate angiogenesis (Figure 4-13). Since C26 tumor-
induced muscle wasting can be completely reversed by tumor removal, TSC-1 
phosphorylation is a strong candidate for IKKI3-dependent, NF-KB-independent 
regulation of cachexia [83]. Treatment strategies targeted at blocking the 
phosphorylation of TSC-1 might ameliorate cachexia by inhibiting tumor growth, 
thereby reducing the release of cytokines or other factors secreted by the tumor 
resulting in the development of muscle atrophy. Figure 4-13 depicts the IKK13-
mediated phosphorylation of TSC-1 and the regulation of angiogenesis in tumor 
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development. 
IKKI3 also has kinase activity on p53, a known tumor suppressor protein . 
Phosphorylation of p53 results in poly-ubiquitination of p53 and the targeting of 
p53 for proteasomal degradation by the 26S proteasome. Degradation of p53 
destroying its tumor suppressor activity and permits tumor growth (Figure 4-13). 
This pathway represents another promising IKKI3-dependent, NF-KB-independent 
signaling cascade through which tumor-induced cachexia might be regulated 
[83]. 
IKKI3 has NF-KB-independent kinase activity on Fox03a, but its NF-KB-
independent kinase activity is not likely to regulate tumor-induced cachexia. 
Foxo transcription factors are known to be involved in other types of skeletal 
muscle wasting such as atrophy triggered by glucocorticoid/dexamethasone 
treatment [144], TNF-a treatment [145] , sarcopenia [146] , fasting [27, 147, 148], 
diabetes [27, 148], sepsis [28] , uremia [27] , hindlimb unloading [94] , and cast 
immobilization [149] and there is a growing body of literature to support the role 
of Fox03a in tumor-induced cachexia as well [27-29, 43, 45, 62] but tumor-
induced cachexia is not likely to be regulated through IKKI3 kinase activity. 
In vivo studies support the role of active, unphosphorylated FoxO in LLC 
and C26 tumor-induced atrophy. 14-day LLC tumor-bearing mice had a 22% 
decrease in muscle fiber cross sectional area compared to non tumor-bearing 
controls. In the muscles of tumor-bearing mice, Fox01 and Fox03 mRNA levels 
and atrogin-1/MAFbx and MuRF1 were upregulated, but not Fox04. FoxO-
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dependent luciferase reporter activity increased. Inhibition of FoxO by 
overexpression of d.n. FoxO completely blocked the increase in FoxO-dependent 
reporter activity, completely blocked the increase in atrogin-1/MAFbx and 
MuRF1, and abolished LLC tumor-induced fiber atrophy [28]. These studies 
show that increased binding of unphosphorylated FoxO transcription factors drive 
LLC tumor-induced wasting, so IKKI3 kinase activity on FoxO is unlikely to 
regulate tumor-induced atrophy. 
Unphosphorylated, nuclear FoxO transcription factors bound to DNA in the 
nucleus increase the transcription of the E3 ubiquitin ligases atrogin-
1/Fbxo32/MAFbx and Trim63/MuRF1 [2, 12, 29, 34, 36, 43, 150]. As discussed 
in the introduction, increases in protein levels or mRNA levels of components of 
the ubiquitin-proteasome degradation pathway are commonly used as a measure 
of muscle atrophy [13 , 41]. Our in vivo microarray data showed an increase in 
atrogin-1/Fbxo32/MAFbx (4.35-fold) and MuRF1/Trim63 (7.25-fold) mRNA in the 
muscle homogenates of late-stage cachectic C26 tumor-bearing animals, 
implying that tumor-bearing animals have increased proteolysis rates. The 
microarray results are in agreement with the literature showing a 12-fold increase 
in the mRNA of atrogin-1/Fbxo32/MAFbx and an 18-fold increase in the mRNA of 
Trlm63/MuRF1 in moderate stage cachexia (1 0% total body mass loss) and a 5-
fold increase in mRNA of both atrogin-1 and MuRF1 during severe cachexia 
(15% total body mass loss) [41 ]. The IKKI3 phosphorylation of Fox03a, and its 
subsequent polyubiquitination, exportation from the nucleus, and degradation by 
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the proteasome, should result in a decrease in protein degradation via the 
inhibition of apoptosis and the activation of cell proliferation [22, 28, 83, 85] rather 
than an increase in protein degradation, which is observed during cancer 
cachexia . In short, IKK~ kinase activity on FoxO should reduce atrophy, rather 
than increase it. Therefore, these studies do not support the IKK~ 
phosphorylation of FoxO as mechanism through which tumor-induced cachexia 
operates. However, there is always the possibility FoxO signaling could be 
modulated by cross-talk with other pathways such as p53 and that there could be 
indirect regulation of tumor-induced cachexia [83, 85]. 
Although IKK~ has not been shown to have direct kinase activity on 
C/EBP~ and STAT3, there may be indirect IKK~ activity via cross-talk between 
different signaling pathways. Recent studies support a role of C/EBP and STAT3 
in regulating tumor-induced cachexia. The involvement of C/EBP has been 
demonstrated in LLC CM-treated C2C12 cells and in LLC tumor-inoculated mice. 
Inhibition of C/EBP attenuates LLC tumor-induced losses in body mass, muscle 
mass, and fiber cross sectional area [45]. Although C/EBP~ appears to be 
required for LLC-induced wasting, it might not be required for cachexia induced 
by C26 carcinoma. 
STAT transcription factors have also recently been linked to tumor-induced 
skeletal muscle atrophy in cell culture and in vivo [41]. STAT3 mRNA levels and 
phosphorylated STAT3 protein levels increase 3-4 fold in C26 tumor-bearing 
mice compared to controls [41], but overexpression of d.n. STAT3 or of shRNA 
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against STAT3 almost completely blocks C26 tumor-induced muscle wasting as 
well as the increase in nuclear binding of phospho-STAT3 [56]. Our lab has not 
been able to replicate these results in C26 tumor-bearing mice injected with d.n. 
STAT3 (unpublished results). The difference in findings could be related to 
differences in the C26 clone used for inoculation , in the transfection method of 
d.n. STAT, or in the timepoints used for plasmid injection , tumor inoculation or 
tissue harvest. 
It might be interesting to test the activity of other IKB isoforms in tumor-
induced cachexia. While we found less attenuation of tumor-induced atrophy 
with overexpression of the IKBaSR compared to d.n. IKK~-EGFP , we did not test 
the possibility that other isoforms of IKB might have altered activity levels and 
would be able to compensate for the loss of normal degradative function of IKBa 
during overexpression of the IKBa-SR in C26 tumor-bearing mice. Some of these 
other isoforms of IKB associate more strongly with non-classical NF-KB dimers 
such as ReiB, p50, and p52. Although the western blot did not reveal any 
change in p100 or p52 in tumor-bearing animals compared to controls , we did not 
evaluate levels of p50 or Bcl-3. Bcl-3, known to be involved in unloading-induced 
atrophy [91-95], could also have a role in tumor-induced atrophy. Bcl-3 mRNA is 
upregulated 2.58-fold in muscle homogenates from tumor-bearing mice 
compared to controls in our gene expression analysis and is upregulated 2.14-
fold in the gene expression analysis using celllysates from 4 h C26 conditioned 
medium-treated C2C12 myotubes (unpublished data). It would be interesting to 
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measure the Bcl-3 mRNA expression levels in mouse muscles and/or C2C12 
myotubes transfected with d.n. IKK13 to see if the C26-induced upregulation of 
Bcl-3 is blocked in the presence of d.n. IKKI3. 
Another promising avenue of research is the identification of target genes 
using ChiP-seq. We recently showed that when an NF-KB transcription factor is 
unequivocally required for muscle atrophy, ChiP-seq is a powerful tool that 
further validates the requirement of the factor by means of the functional 
categories of genes showing transcription factor binding peaks [93] ; this was not 
the case in C26 cancer for p65 ChiP-seq . An explanation for this appears in 
several papers that do find p65 binding sites by ChiP-seq in which the induction 
of p65 binding requires strong inflammatory mediators such as LPS [130] or 
TNFa [131 , 151]. We showed in Figure 4-12A that incubation with TNFa 
produces IP-10 p65 binding in treated C2C12 cells , however, the IP-10 gene did 
not show increased p65 binding due to C26-mediated cachexia (Figure 4-128). 
Corroborating this , our gene expression array for control vs. C26 muscle showed 
that IP-10 mRNA levels were unchanged (not shown in Table 51 because there 
was no change) . C26-induced cachexia does not appear to be mediated by the 
kind of inflammatory cytokines that would produce p65 activation. 
The lack of binding peaks on genes involved in atrophy processes could be 
due to our measurement of binding at only one time point, severe cachexia (Day 
25). However, at the time of severe cachexia our microarray data show that the 
expression of genes that characterize muscle wasting is ongoing, so at least p65 
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shows little direct involvement in activation of genes at this time. In addition, the 
overexpression of d.n . p65 or d.n. c-Rel would have shown a significant blocking 
of muscle atrophy if these NF-KB factors were required at an earlier time point in 
cachexia. Moreover, NF-KB reporter assays and gel shift assays were done at 
several time points, from 12 to 25 days post-tumor cell inoculation, and at no time 
was there an activation of the reporter nor a significant increase in binding to an 
NF-KB oligonucleotide, unlike the robust increase we showed in a primary muscle 
inflammatory disease (Figure 4-BC) or in disuse atrophy [92]. 
For the first time we show that IKKI3 is required for the development of 
cancer cachexia, but IKKa and NIK are not. Our in-depth analysis of NF-KB 
signaling and transcription during cancer cachexia shows that IKKI3 may regulate 
gene expression by transcription factors other than NF-KB, ?t least in skeletal 
muscle during C26 cancer cachexia. Thus, NF-KB transcription is not driving the 
C26 tumor-induced muscle wasting process, as evidenced by a lack of an effect 
on atrophy due to genetic inhibition of two out of the three Rei proteins containing 
transactivation domains (c,.Rel and p65/Rel A), the lack of increased NF-KB 
protein binding in gel shift and reporter assays, and the lack of atrophy target 
gene binding of the prototypical Rei transcription factor p65 in genome-wide 
ChiP-seq experiments. These results reveal an unexpected but important facet 
of the regulation of cancer-induced muscle wasting. 
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Figure 4-13. IKKJ3-dependent, NF-KB-independent signaling pathways 
leading to tumor angiogenesis or tumor growth. Known signaling pathways 
by which IKK~ kinase activity regulates tumor growth or angiogenesis. Inhibition 
of IKK~ kinase activity on Tsc1 and on p53 would inhibit C26 tumor-induced . 
skeletal muscle atrophy by blocking tumor angiogenesis or tumor growth. 
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Supplemental Figures 
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Figure 51. Verification of the inhibiting effect of the dominant-negative 
forms of p65 and c-Rel. (A) A test of d.n. p65-EGFP by treatment of myotubes 
for 4 hours with 10 ng/ml mouse TN Fa. c-Rel-mediated NF-KB activity does not 
respond to TNFa in C2C12 cells , but the resting level of NF-KB activity is 
determined in part by c-Rel as shown in B. (B) C2C 12 cells transfected with a 
NF-KB reporter plus control (pEGFP) , d. n. p65-EGFP fusion plasmid, or d.n. c-
Rei-EGFP fusion plasmid . 
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Figure 52. Western blots of phospho-IKBa and IKBa in control and C26 
muscle. (A) Gastrocnemius muscle extracts from mice 10 days post inoculation. 
(B) Gastrocnemius muscle extracts from mice 24 days post inoculation. 60 1-19 
protein loaded per lane. Each lane represents an independent muscle sample. 
There were no changes in p-IKBa or IKBa expression due to either time point of 
cachexia. 
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Figure 53. FastQC printout for bam format of C26 p65 ChiP-seq. FastQC 
evaluates the ChiP-seq alignment data on 11 criteria. The output in this case 
passed all tests and was then used for peak analysis. 
104 
la/U/11 
~FastQC Report 
Summary 
@ Basic Statistics 
@ Per bMft5ftQYPI!Ce gyalily 
@ Pftr soouence QllfllitX 5C(Uft5 
@ Per base segyepce content 
a Per base GC coplent 
@ Per sequence GC content 
@ Per base N content 
Sooyepce Length Distribution 
@ sequence DuPlication Levels 
@ OVerrepresented muencg; 
@ Kmer Coplent 
@ Basic Statistics 
Value 
Galiaxyl62-[l061 0B . b im ] . b ... 
F il.e t :rpe 
Encodi1141 sanger I Illlllllilla l.9 
1112 
Mon 7 Oct 2013 
Galaxy162~1061 08.blllml.bam 
Figure 54. FastQC printout for bam format of Control p65 ChiP-seq. The 
sequences passed all tests and were taken for peak analysis. 
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Figure 55. FastQC printout for bam format of no antibody ChiP-seq 
(background). The background alignments passed all tests and were used as 
the input reference for the ChiPseeqer program. 
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Figure 56. Effect of C26 conditioned medium on C2C12 myotube diameter. 
Mean C2C12 myotube diameter in control and 24 h, 25.0% C26 conditioned 
medium-treated cell culture plates. Myotubes were differentiated 3 days before 
treatment. Each bar represents the mean of myotube diameter measurements 
from 3 wells, 300-330 myotubes per group. C26 conditioned medium-treated 
myotubes were 20.0% (± SE) smaller in diameter than untreated controls. 
*significantly different from control (P<0.05). 
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Figure 57. Effect of d.n. IKKJ3-EGFP on C26 conditioned medium-induced 
C2C12 myotube diameter atrophy. Mean C2C12 myotube diameter in control 
and 48 h, 33.3% C26 conditioned medium-treated cell culture plates with and 
without transfection of d.n. IKKI3-EGFP. Myotubes were differentiated 3 days 
before treatment. Each bar represents the mean of myotube diameter 
measurements from 3 wells per group , 250-550 myotube measurements per 
group. Untransfected C26 conditioned medium-treated myotubes were 18.9% (± 
SE) smaller in diameter than untransfected, untreated controls . The presence of 
d .n. IKKI3-EGFP completely blocked C26 CM-induced myotube atrophy. 
*significantly different from control (P<0.05) . t significantly different from C26 
CM-treated myotubes not transfected with d.n. IKKI3-EGFP (P<0 .05). 
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Figure 58. Effect of IKBa-SR-EGFP on C26 conditioned medium-induced 
C2C12 myotube diameter atrophy. Mean C2C12 myotube diameter in control 
and 48 h, 33.3% C26 conditioned medium-treated cell culture plates with and 
without transfection of IKBa-SR-EGFP. Myotubes were differentiated 5 days 
before treatment. Each bar represents the mean of myotube diameter 
measurements from 2-3 wells per group, 85-180 myotube measurements per 
group. Untransfected C26 conditioned medium-treated myotubes were 18.0% (± 
SE) smaller in diameter than untransfected, untreated controls. The presence of 
IKBa-SR-EGFP completely blocked C26 CM-induced myotube atrophy. 
*significantly different from control (P<0.05). t significantly different from C26 
CM-treated myotubes not transfected with IKBa-SR-EGFP (P<0.05). 
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Figure 59. Effect of helenalin (p65 inhibitor) on C26 conditioned medium-
induced C2C12 myotube diameter atrophy. Mean C2C12 myotube diameter 
in control and 48 h, 25.0% C26 conditioned medium-treated cell culture plates 
with and without helenalin (11JM). Myotubes were differentiated 3 days before 
treatment. Each bar represents the mean of myotube diameter measurements 
from 3 wells per group, 300-330 myotub~ measurements per group. 
Untransfected C26 conditioned medium-treated myotubes were 20.0% (± SE) 
smaller in diameter than untransfected, untreated controls. The presence of 
helenalin did not significantly block C26 CM-induced myotube atrophy. 
*significantly different from control (P<0.05). 
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Figure 510. NF-KB-dependent luciferase reporter activity in C26 
conditioned medium-treated C2C12 myotubes. NF-KB-dependent luciferase 
reporter activity in celllysates from 4-day differentiated C2C12 myotubes 
transfected with NF-KB luciferase reporter plasmid and treated with C26 
conditioned medium for 2, 4, 8, and 24 h (n=4 wells per group) . The luciferase 
reporter activity values for each treatment time were normalized to the value for 
the untreated, control myotubes. 
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Table 51. Cachexia-induced up-regulated genes (~1.5-fold) belonging to DAVID-identified 
GO categories 
Term Count P-Value Benjamini Genes in category 
G0:0006508- 87 6.32E-05 0.0083834 AEBP1 , LGMN, MMP8, HP, RNF216, MMP3, 
proteolysis RLIM, C1QC, DDI2, CASP4, MAP1LC3B, 
CFH, RANBP2, HTRA3, DPEP1, CUL 1, 
USP14, PSMD8, TBL 1XR1, C4B, SOCS3, 
DDB1 , USP1 , ENC1 , MMP19, HERC4, 
SERPING1 , UBR2, MMP14, PSMA2, C1QA, 
C1QB, USP28, PSMA1 , CTSL, UHRF2, 
PSMA6, PSEN1, PIAS4, PSMA5, SIAH1A, 
CPXM1, UBC, CTSD, UBB, ASB5, ADAMTS4, 
RAD23B, USP30, OTUD5, USP3, C3, ASB11 , 
CBLL 1, C1S, PSMA7, 4833403115RIK, 
EDEM1 , RNF125, PSMB4, ECE1 , PSMB1 , 
PSMB3, PSMB2, FBX06, USP36, FBX04, 
NEDD4L, HECTD1 , NPLOC4, UBE4A, SPSB1 , 
LRRC41 , PM20D2, UBE4B, MAL T1 , TRIM63, 
MID1 , TINAGL 1, CBLB, CRBN, SPCS3, 
FBX030, ZRANB1 , FBX031 , FTSJD2, 
FBX032, USP42 
G0:0009057-m 75 3.49E-09 4.65E-06 CAST, PGLYRP1, BNIP3, RNF216, RLIM , 
aero-molecule AKT1 , MAP1LC3B, RANBP2, MYC, USP14, 
catabolic CUL 1, ZFP36, TBL 1XR1 , SOCS3, DDB1 , 
process USP1 , ENC1 , HERC4, UBR2, PSMA2, USP28, 
PSMA1 , UHRF2, CD36, PSEN1 , PIAS4, 
PSMA6, PSMA5, SIAH1A, GAA, UBC, UBB, 
ASB5, RAD23B, OTUD5, USP30, USP3, 
ASB11, CBLL1 , PSMA7, EDEM1 , RNF125, 
PSMB4, PSMB1 , EIF3E, PSMB3, PSMB2, 
FBX06, USP36, FBX04, NEDD4L, HECTD1 , 
NPLOC4, UBE4A, SPSB1 , LRRC41 , UBE4B, 
CHI3L 1, SMG1 , MAL T1 , CHI3L3, TRIM63, 
MID1 , L YVE1 , CBLB, PSMC6, PSMC4, 
PSMC3, PSMC2, PSMC1 , FBX030, ZRANB1 , 
FTSJD2, FBX031 , FBX032, USP42 
G0:0030163- 64 4.97E-08 3.31 E-05 CAST, RNF216, RLIM, AKT1 , MAP1LC3B, 
protein catabolic RANBP2, USP14, CUL 1, TBL 1XR1 , SOCS3, 
process DDB1 , USP1 , ENC1 , HERC4, UBR2, PSMA2, 
USP28, PSMA1 , UHRF2, PSEN1 , PIAS4, 
PSMA6, PSMA5, SIAH1A, UBC, UBB, ASB5, 
RAD23B, OTUD5, USP30, USP3, ASB11 , 
CBLL 1, PSMA7, EDEM1 , RNF125, PSMB4, 
PSMB1, PSMB3, PSMB2, FBX06, FBX04, 
USP36, NEDD4L, HECTD1 , NPLOC4, UBE4A, 
SPSB1 , LRRC41 , UBE4B, MALT1 , TRIM63, 
MID1 , CBLB, PSMC6, PSMC4, PSMC3, 
PSMC2, PSMC1 , FBX030, ZRANB1 , FTSJD2, 
FBX031 , FBX032, USP42 
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G0:0044265- 63 2.73E-06 9.09E-04 BNIP3, RNF216, RLIM, MAP1 LC3B, RANBP2, 
cellular macro- MYC, USP14, CUL1 , ZFP36, TBL1XR1 , 
molecule SOCS3, DDB1 , USP1 , ENC1 , HERC4, UBR2, 
catabolic PSMA2, USP28, PSMA 1, UHRF2, CD36, 
process PSEN1 , PIAS4, PSMA6, PSMA5, SIAH1A, 
UBC, UBB, ASB5, RAD23B, OTUD5, USP30, 
USP3, ASB11 , CBLL 1, PSMA7, EDEM1 , 
RNF125, PSMB4, PSMB1 , PSMB3, EIF3E, 
PSMB2, FBX06, FBX04, USP36, NEDD4L, 
HECTD1 , NPLOC4, UBE4A, SPSB1 , LRRC41 , 
UBE4B, SMG1 , MALT1 , TRIM63, MID1 , CBLB, 
FBX030, ZRANB1 , FTSJD2, FBX031 , 
FBX032, USP42 
G0:0051603- 57 3.32E-06 9.81 E-04 RNF216, RLIM, MAP1 LC3B, RANBP2 , USP14, 
proteolysis CUL 1, TBL 1XR1 , SOCS3, USP1 , DDB1 , 
involved in ENC1 , HERC4, UBR2, PSMA2, USP28, 
cellular protein PSMA1, UHRF2, PSEN1 , PIAS4, PSMA6, 
catabolic PSMA5, SIAH1A, UBC, UBB, ASB5, RAD23B, 
process OTUD5, USP30, USP3, ASB11 , CBLL 1, 
PSMA7, EDEM1 , RNF125, PSMB4, PSMB1 , 
PSMB3, PSMB2, FBX06, FBX04, USP36, 
NEDD4L, HECTD1 , NPLOC4, UBE4A, SPSB1 , 
LRRC41 , UBE4B, MALT1 , TRIM63, MID1 , 
CBLB, FBX030, ZRANB1 , FTSJD2, FBX031 , 
FBX032, USP42 
G0:0044257- 57 3.98E-06 0.00106 RNF216, RLIM, MAP1 LC3B, RANBP2, USP14, 
cellular protein CUL 1, TBL 1XR1 , SOCS3, USP1 , DDB1 , 
catabolic ENC1 , HERC4, UBR2, PSMA2, USP28, 
process PSMA1 , UHRF2, PSEN1 , PIAS4, PSMA6, 
PSMA5, SIAH1A, UBC, UBB, ASB5, RAD23B, 
OTUD5, USP30, USP3, ASB11 , CBLL 1, 
PSMA7, EDEM1 , RNF125, PSMB4, PSMB1 , 
PSMB3, PSMB2, FBX06, FBX04, USP36, 
NEDD4L, HECTD1 , NPLOC4, UBE4A, SPSB1 , 
LRRC41 , UBE4B, MALT1 , TRIM63, MID1 , 
CBLB, FBX030, ZRANB1 , FTSJD2, FBX031 , 
FBX032, USP42 
G0:001 0033- 53 8.86E-06 0.0019634 FOX01 , SERPINA3C, TLR4, AKT1 , 
response to EIF4EBP1 , MYD88, HMOX1 , IL 1 B, LBP, INSR, 
organic MYC, AKIRIN2, EIF2B5, IRS2, C5AR1 , RELA, 
substance MGP, MMP14, LPIN1 , GLUL, SERPINA3N, 
SERPINA3H , EIF4A2, ERN1 , NFE2L2, 
PPP1R15A, CYP1B1 , MCL 1, BCL2L 1, VARS, 
EDEM1, PHIP, IRAK3, SORBS1 , ADH1 , 
FBX06, PIK3R1, NOS1, PTPN2, KLF10, 
TGFBR1 , TGFBR2, MALT1 , HERPUD2, 
EIF2B1 , STAT3, EPS8, GCK, MTOR, PTPN1 , 
CD14, UBXN4, SLC9A1 
G0:0006952- 52 2.62E-07 1.16E-04 ALS2, RARRES2, TOLLIP, TBK1 , PGLYRP1 , 
defense BNIP3, TLR4, SGMS1 , C1QC, AKT1 , 
response TMEM173, MYD88, SAA1 , CFH, IL 1 B, LBP, 
AKIRIN2, PLD1 , C5AR1 , NGP, C4B, RELA, 
113 
MECP2, SERPING1 , CD163, C1QA, C1QB, 
SERPINA3N, DARC, IL 1R1 , C3, ITGB2, C1S, 
VARS, PLAA, TNFRSF1A, BCL3, THBS1 , 
84GAL T1 , SELP, TLR 13, SAMHD1 , CHI3L3, 
MAL T1 , STAT3, POLR3E, FCGR28, CXCL 13, 
SLC7A2, BNIP3L, IGFBP4, CD14 
G0:0043632-m 52 3.18E-05 0.0049662 RNF216, RLIM, MAP1 LC38, RANBP2, USP14, 
odification- CUL 1, TBL 1XR1 , SOCS3, USP1 , DDB1 , 
dependent ENC1 , HERC4, UBR2, PSMA2, USP28, 
macro-molecule PSMA1 , UHRF2, PIAS4, PSMA6, PSMA5, 
catabolic SIAH1A, USC, USB, ASB5, OTUD5, USP30, 
process RAD238, USP3, ASB11 , CBLL 1, PSMA7, 
EDEM1 , RNF125, FBX06, FBX04, USP36, 
NEDD4L, HECTD1 , NPLOC4, SPSB1 , UBE4A, 
LRRC41 , UBE48, MALT1 , TRIM63, MID1 , 
CBLB, FBX030, FTSJD2, FBX031 , ZRANB1 , 
FBX032, USP42 
G0:0019941-m 52 3.18E-05 0.0049662 RNF216, RLIM , MAP1 LC38, RANBP2, USP14, 
odification- CUL 1, TBL 1XR1 , SOCS3, USP1 , DDB1 , 
dependent ENC1 , HERC4, UBR2, PSMA2, USP28, 
protein catabolic PSMA 1, UHRF2, PIAS4, PSMA6, PSMA5, 
process SIAH1A, USC, USB, ASB5, OTUD5, USP30, 
RAD238, USP3, ASB11 , CBLL 1, PSMA7, 
EDEM1 , RNF125, FBX06, FBX04, USP36, 
NEDD4L, HECTD1 , NPLOC4, SPS81 , UBE4A, 
LRRC41 , UBE48, MALT1 , TRIM63, MID1 , 
CBLB, FBX030, FTSJD2, FBX031 , ZRANB1 , 
FBX032, USP42 
G0:0006396-R 48 1.24E-05 0.002349 RPP38, FIP1 L 1, RNASEL, ELAC2, RNMT, 
NA processing UTP15, TRMT1 , XAB2, SMNDC1 , DIMT1 , 
SF38 1, UTP11 L, METTL 1, DHX 15, DDX20, 
NSUN2, FTSJ3, PPWD1 , GEMIN5, ZFP36, 
PHRF1 , ADARB1 , NOL3, LCMT2, 
MPHOSPH10, SF1 , PRPF39, SNW1 , 
EXOSC1 , TRMT61A, RPF1 , PRPF6, RSL 1 D1 , 
TRNT1 , NOP14, SNRNP48, PA2G4, DDX56, 
PAPD4, ERN1 , SYF2, ZRANB2, UTP14A, 
PES1 , CSTF1 , RBM17, SSU72, DDX51 
G0:0009611- 39 3.57E-05 0.0049908 C3, TOLLIP, F13A1 , ITGB2, TLR4, C1S, 
response to SGMS1 , TRIM72 , C1QC, AKT1 , PLAA, 
wounding TNFRSF1A, MYD88, PROCR, SAA1 , CFH, 
IL1 8 , LBP, THBS1 , ENTPD1 , 84GAL T1 , KLF6, 
SELP, C4B, TLR13, TGFBR2, CHI3L3, 
SERPING1, STAT3, CD163, C1QA, C1QB, 
SERPINA3N, DARC, SLC7A2, CXCL 13, 
PROS1 , CD14, IGFBP4 
G0:0006954- 32 1.78E-06 6.76E-04 C3, TOLLIP, ITGB2, TLR4, C1S, SGMS1 , 
inflammatory C1QC, AKT1 , PLAA, TNFRSF1A, MYD88, 
response SAA1 , CFH, IL18, LBP, THBS1 , 84GALT1 , 
SELP, C48, TLR13, CHI3L3, SERPING1 , 
STAT3, CD163, C1QA, C1QB, SERPINA3N, 
DARC, SLC7A2, CXCL 13, CD14, IGFBP4 
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80:0022613- 28 6.06E-09 5.38E-06 SDAD1 , UTP15, SMNDC1 , DIMT1 , UTP11 L, 
Ribonucleo- SBDS, EIF3A, NPM1 , BRIX1 , AATF, 8NL2, 
protein complex FTSJ3, NMD3, 8TPBP4, TSR1 , MPHOSPH10, 
biogenesis EXOSC1 , RPF1 , NOP14, DDX56, PA284, 
IP04, NOP58, RRS1 , NOP56, PES1 , UTP14A, 
DDX51 
80:0042254- 26 1.38E-09 3.67E-06 SDAD1 , UTP15, DIMT1 , UTP11L, SBDS, 
ribosome NPM1 , BRIX1 , AATF, 8NL2, FTSJ3, NMD3, 
biogenesis 8TPBP4, TSR1 , MPHOSPH10, EXOSC1 , 
RPF1 , NOP14, DDX56, PA284, IP04, NOP58, 
RRS1 , NOP56, PES1 , UTP14A, DDX51 
80:0006511- 26 2.61 E-07 1.39E-04 USP30, RAD23B, USP3, PSMA7, EDEM1 , 
ubiquitin- FBX06, FBX04, USP36, CUL 1, USP14, 
dependent TBL 1XR1 , NPLOC4, UBE4A, USP1 , UBE4B, 
protein catabolic UBR2, TRIM63, PSMA2, USP28, PSMA 1, 
process UHRF2, PSMA6, PSMA5, SIAH1A, FBX031 , 
USP42 
80:0009725- 24 3.25E-05 0.0047987 IRS2, PTPN2, T8FBR1 , T8FBR2, M8P, 
response to FOX01 , SERPINA3C, MMP14, EIF2B1 , 
hormone LPIN1 , STAT3, AKT1 , PHIP, SERPINA3N, 
stimulus EIF4EBP1 , SERPINA3H, SORBS1 , ADH1 , 
HMOX1 , MTOR, PTPN1 , INSR, PIK3R1 , 
EIF2B5 
80:0045087- 19 2.26E-05 0.0037485 IL 1R1 , C3, C4B, TBK1 , TLR13, SAMHD1 , 
innate immune SERPIN81 , TLR4, MALT1 , C1S, C1QC, 
response POLR3E, C1QA, C1QB, TMEM173, MYD88, 
CFH, LBP, AKIRIN2 
80:0043434- 18 1.21 E-05 0.0024655 IRS2, PTPN2, FOX01 , SERPINA3C, EIF2B1 , 
response to LPIN1 , STAT3, AKT1 , PHIP, SERPINA3N, 
peptide EIF4EBP1 , SERPINA3H, SORBS1 , MTOR, 
hormone PTPN1 , INSR, PIK3R1 , EIF2B5 
stimulus 
80:0002526- 17 4.49E-06 0.0010869 B48AL T1, C3, C4B, SERPIN81 , TLR4, C1 S, 
acute C1QC, STAT3, CD163, C1QA, C1QB, 
inflammatory SERPINA3N, SAA1 , SLC7A2, CFH, IL 18, LBP 
response 
80:0009894- 12 6.61 E-05 0.0083407 AKT1 , IRAK3, NPC1 , CBLB, ML YCD, RELA, 
regulation of PSMD1, PSMD2, IL 1 B, PSMD3, PNPLA2, 
catabolic MTOR 
I process 
80:0008286- 10 1.38E-05 0.0024472 AKT1 , PHIP, IRS2, EIF4EBP1 , SORBS1 , 
insulin receptor PTPN2, FOX01 , PTPN1 , INSR, PIK3R1 
signaling 
I pathway 
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Table 51. Cachexia-induced down-regulated genes (~1.5-fold) belonging to DAVID-identified 
GO categories 
Term Count P-Value Benjamini Genes 
G0:0055114- 61 7.86E-08 8.62E-05 8TEAP3, TM78F2, CY85R1 , D2HGDH, 
oxidation UQCRC1 , KCNA81 , CYC1, ALDH1L2, P4HA1 , 
reduction NDUF88, 8MOX, A8PH , LOXL2, RTN41P1 , 
NDUF81, NQ02, NOUF810, NOUFC2, QOPR, 
NOUFC1 , COQ7, OHR87C, DHR81 , KOM28, 
AKR 1 810, CY8R01 , OXNA01 , LEPREL 1, 
ZAOH2, PCYOX1 , AOC3, MDH1 , CYP2U1 , 
NOUF86, NOUF87, NDUF88, NOUF89, EGLN1 , 
NOUF82, C8R2, OHCR7, NMRAL 1, FA8N, 
8CD1 , GP02, GP01 , 8C02, PTGR2, NOUFA8, 
MA08, DHR811 , FA082, CRYZ, TET1 , IOH3A, 
8002, M8R83, 80H8, AKR1 83, 80HO, 
2610507811 RIK 
G0:0006091- 36 2.42E-09 5.30E-06 PRKAG3, NOUF86, UQCRC1 , NOUF87, 
generation of NDUF88, NDUF89, PHKA1 , 8LC37A4, CYC1 , 
precursor HK2, PGAM2, ATP5G1 , ATP5G3, NDUF82, TPI1 , 
metabolites NOUF88, ATP5H, NOUF81 , ATP5K, EN01 , 
and energy NOUF810, NOUFA8, PHKG1 , EPM2A, NOUFC2, 
FA082, 8PGM, NOUFC1 , OLAT, IDH3A, 8002, 
8DH8, 8DHD, CY8R01 , 2610507811 RIK, MOH1 
G0:0043062- 24 1.15E-07 8.38E-05 TNC, OLFML28, COL3A 1, H8PG2, OLFML2A, 
extracellular P08TN, KY, COL2A1 , ECM2, COL5A3, 
structure CACNA18, 8ERPINH1 , COL5A2, APLP2, 
organization COL5A1 , A8138P, TGF82, EGFLAM, P4HA1, 
KAZAL01 , OOK7, PAK1, COL11A1 , OPT 
G0:0030198- 19 2.93E-07 1.60E-04 OLFML28, COL3A1 , H8PG2, OLFML2A, P08TN, 
extracellular COL2A1 , ECM2, COL5A3, 8ERPINH1 , COL5A2, 
matrix APLP2 , A8138P, COL5A1 , TGF82, EGFLAM, 
organization P4HA 1, KAZALD1 , COL 11 A 1, OPT 
G0:0014706- 19 9.23E-06 0.0033688 MEF2C, MY001 , R8P4, ACTC1 , TNC, RXRG, 
striated H8PG2, MYLPF, EGLN1 , KY, C8Y1, HOMER1 , 
muscle tissue CACNA18, HOX010, TGF82, OOK7, RAR8, 
development PAK1 , COL11A1 
G0:0060537- 19 2.42E-05 0.0066152 MEF2C, MY001 , R8P4, ACTC1 , TNC, RXRG, 
muscle tissue H8PG2, MYLPF, EGLN1 , KY, C8Y1 , HOMER1 , 
development CACNA18, HOXD10, TGF82, OOK7, RAR8, 
PAK1 , COL11A1 
G0:0022900- 18 6.31E-06 0.0027625 UQCRC1 , NDUF86, NDUF810, NDUFA8, 
electron NDUFB7, NDUFB8, NDUFB9, CYC1 , NDUFC2, 
transport FA082, NDUFC1 , NOUFB2, 8002, 8DH8, 
chain 80HO,NDUF88, CY8R01 , NDUF81 
G0:0030199- 8 2.03E-05 0.0063549 P4HA1 , COL3A1 , COL2A1 , COL11A1 , 
collagen fibril 8ERPINH1 , COL5A2, COL5A1 , OPT 
organization 
Table .S1. Differentially expressed genes due to cancer (q<0.05, p<0.05, 
2::1 .5-fold change) 
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Enriched GO terms in up-regulated genes Count 
G0:0006508: proteolysis 87 
G0:0009057: macromolecule catabolic process 75 
G0:0030163: protein catabolic process 64 
G0:0044265: cellular macromolecule catabolic process 63 
G0:0051603: proteolysis involved in cellular protein catabolic process 57 
G0:0044257: cellular protein catabolic process 57 
G0:001 0033: response to organic substance 53 
G0:0006952: defense response 52 
G0:0043632: modification-dependent macromolecule catabolic process 52 
G0:0019941: modification-dependent protein catabolic process 52 
G0:0006396: RNA processing 48 
G0:0009611: response to wounding 39 
G0:0006954: inflammatory response 32 
G0:0022613: ribonucleoprotein complex biogenesis 28 
G0:0042254: ribosome biogenesis 26 
G0:0006511: ubiquitin-dependent protein catabolic process 26 
G0:0009725: response to hormone stimulus 24 
G0:0045087: innate immune response 19 
G0:0043434: response to peptide hormone stimulus 18 
G0:0002526: acute inflammatory response 17 
G0:0009894: regulation of catabolic process 12 
G0:0008286: insulin receptor signaling pathway 10 
Enriched GO terms in down-regulated genes Count 
G0:0055114: oxidation reduction 61 
G0:0006091 : generation of precursor metabolites and energy 36 
G0:0043062: extracellular structure organization 24 
G0:0030198: extracellular matrix organization 19 
G0:0014706: striated muscle tissue development 19 
G0:0060537: muscle tissue development 19 
G0:0022900: electron transport chain 18 
G0:0030199: collagen fibril organization 8 
*Count denotes the number of up/down-regulated genes associated w1th each GO term. 
Table 52. Cachexia-induced up- and down-regulated genes (~1 . 5-fold) 
belonging to DAVID-identified GO categories shown in Table 1. 
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Table 53. Up-regulated and down-regulated genes 
Up-regulated genes 
Fold 
Gene Abbr Gene Name p value Change 
Ubiquitin -proteasome 
Cul1 cullin 1 1.40E-03 1.61 
Fbxo30 F-box protein 30 1.33E-03 2.08 
Fbxo31 F-box protein 31 7.14E-05 2.92 
Fbxo32 F-box protein 32 3.33E-05 4.35 
Fbxo4 F-box protein 4 6.00E-03 1.55 
Fbxo6 F-box protein 6 2.65E-03 1.63 
Hectd1 HECT domain containing 1 5.57E-06 2.37 
neural precursor cell expressed , 
Nedd41 developmentally down-regulated 4-like 1.66E-04 1.71 
proteasome (prosome, macropain) 
Psma1 subunit, alpha type, 1 1.94E-03 1.96 
proteasome (prosome, macropain) 
Psma2 subunit, alpha type, 2 6.13E-03 1.77 
proteasome (prosome, macropain) 
Psma5 subunit, alpha type, 5 8.00E-04 1.91 
proteasome (prosome, macropain) 
Psma6 subunit, alpha type, 6 4.96E-03 1.7 
proteasome (prosome, macropain) 
Psma7 subunit, alpha type, 7 8.19E-04 2.75 
proteasome (prosome, macropain) 
Psmb1 subunit, beta type, 1 1.10E-02 1.72 
proteasome (prosome, macropain) 
Psmb2 subunit, beta type, 2 8.34E-03 1.73 
proteasome (prosome, macropain) 
Psmb3 subunit, beta type, 3 3.10E-03 1.9 
proteasome (prosome, macropain) 
Psmb4 subunit, beta type, 4 9.81 E-03 1.72 
proteasome (prosome, macropain) 26S 
Psmc1 subunit, ATPase, 1 7.11E-03 1.74 
proteasome (prosome, macropain) 26S 
Psmc2 subunit, ATPase, 2 3.10E-03 2.18 
proteasome (prosome, macropain) 26S 
Psmc3 subunit, ATPase, 3 6.18E-03 1.58 
proteasome (prosome, macropain) 26S 
Psmc4 subunit, ATPase, 4 1.07E-02 1.88 
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proteasome (prosome, macropain) 26S 
Psmc6 subunit, ATPase, 6 3.63E-03 1.75 
proteasome (prosome, macropain) 26S 
Psmd8 subunit, non-ATPase, 8 4.70E-04 1.65 
Rlim ring finger protein, LIM domain interacting 8.89E-05 1.95 
ring finger protein 125, E3 ubiquitin 
Rnf125 protein ligase 8.56E-03 1.53 
Rnf216 ring finger protein 216 3.39E-05 1.91 
Siah1a siah E3 ubiquitin protein ligase 1 2.28E-03 1.82 
Trim63 tripartite motif-containing 63 6.93E-05 7.25 
Ubb ubiquitin B 2.49E-03 4.22 
Ubc ubiquitin C 4.36E-03 2.14 
ubiquitin factor E4B (UFD2 homolog, 
Ube4b yeast) 2.17E-05 1.62 
ubiquitin protein ligase E3 component n-
Ubr2 recognin 2 1.78E-03 1.53 
Autophagy_ 
Atg 13 ATG13 autophagy-related 13 homolog 4.40E-04 1.62 
Atg14 ATG14 autophagy-related 14 homolog 6.13E-04 1.47 
Atg2a ATG2 autophagy-related 2 homolog A 6.44E-03 1.26 
Atg2b ATG2 autophagy-related 2 homolog B 1.29E-04 1.5 
Atg4b ATG4 autophagy-related 4 homolog B 3.34E-04 1.28 
Atg7 ATG7 autophagy-related 7 homolog 2.25E-02 1.27 
BCL2/adenovirus E1 B 19kDa interacting 
Bnip3 protein 3 1.80E-06 2.85 
DNA damage regulated autophagy 
Dram1 modulator 1 9.54E-04 1.38 
DNA damage regulated autophagy 
Dram2 modulator 2 6.30E-03 1.15 
Gaa glucosidase, alpha; acid 1.42E-04 2.38 
Gabarap GABA(A) receptor-associated protein 7.44E-04 1.67 
GABA(A) receptor-associated protein like 
Gabarapl1 1 2.01E-05 5.63 
Ulk1 UNC-51-Iike kinase 1 1.20E-03 2.54 
Other proteolytic pathway 
ADAM metallopeptidase with 
Adamts4 thrombospondin type 1 motif, 4 4.38E-03 1.91 
ankyrin repeat and sacs box-containing 
Asb11 3 4.78E-05 3.23 
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caspase 4, apoptosis-related cysteine 
Casp4 peptidase 8.48E-04 2.21 
Cas-Br-M (murine) ecotropic retroviral 
Cblb transforming sequence B 7.46E-04 2.05 
Cbl proto-oncogene-like 1, E3 ubiquitin 
Cbll1 protein ligase 1.60E-03 1.57 
Ctsl cathepsin L 1 1.95E-06 3.98 
Ctss cathepsin S 1.15E-02 1.51 
Htra3 HtrA serine peptidase 3 2.02E-03 1.88 
Lrrc41 leucine rich repeat containing 41 3.66E-04 1.72 
matrix metallopeptidase 14 (membrane-
Mmp14 inserted) 2.05E-03 1.64 
Mmp19 matrix metallopeptidase 19 2.06E-03 2.11 
matrix metallopeptidase 3 (stromelysin1 , 
Mmp3 progelatinase) 4.50E-04 4.19 
matrix metallopeptidase 8 (neutrophil 
Mmp8 collagenase) 2.21E-04 3.16 
serpin peptidase inhibitor, clade G (C1 
Serping1 inhibitor) , member 1 6.34E-04 1.66 
Immune response 
Cxcr2 chemokine (C-X-C motif) receptor 2 1.64E-04 4.87 
Dare Duffy blood group, chemokine receptor 1.33E-03 2.17 
1113ra1 interluekin 13 receptor, alpha 1 6.05E-05 2.13 
1117ra interleukin 17 receptor A 2.07E-05 2.15 
111 r1 interluekin 1 receptor, type I 8.60E-03 1.82 
111 r2 interleukin 1 receptor, type II 4.49E-04 3.14 
1133 interleukin 33 9.25E-03 1.96 
114ra interleukin 4 receptor 9.70E-05 2.66 
116ra lnterleukin 6 receptor 1.51 E-06 10.97 
interleukin 6 signal transducer (gp130, 
116st oncostatin M receptor) 2.10E-04 1.55 
myeloid differnetiation primary response 
Myd88 gene (88) 3.31 E-05 1.84 
Saa1 serum amyloid A1 8.39E-03 1.75 
Samhd1 SAM domain and HD domain 1 2.39E-04 1.88 
serpin peptidase inhibitor, clade A (alpha-
Serpina3n 1 antiproteinase, antitrypsin), member 3 1.53E-05 16.81 
Tlr13 toll-like receptor 13 3.08E-03 1.61 
Tlr4 toll-like receptor 4 1.89E-03 2.02 
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tumor necrosis factor receptor superfamily 
Tnfrsf12a member 12A 2.80E-02 2.03 
tumor necrosis factor receptor superfamily 
Tnfrsf1a member 1A 1.33E-04 1.72 
Transcription factors 
Bcl3 B-cell CLL/Iymphoma 3 6.64E-05 2.58 
CCAAT/enhancer binding protein 
Cebpb (C/EBP), beta 1.02E-03 2.59 
CCAAT/enhancer binding protein 
Cebpd (C/EBP), delta 2.94E-05 5.51 
FOX01 forkhead box 01 5.92E-07 4.24 
FOX03 forkhead box 03 2.66E-04 2.55 
Junb junB proto-oncogene/activator protein 7.77E-03 2.19 
v-myc myelocytomatosis viral oncogene 
Myc homolog (avian) 5.55E-04 3.01 
Myog myogenin (myogenic factor 4) 3.70E-03 1.68 
Runx1 runt-related transcription factor 1 2.13E-04 2.62 
Smad5 SMAD family memebr 5 5.11 E-05 1.82 
Sox4 SRY (sex determining region Y)-box 4 6.78E-03 1.71 
signal transducer and activator of 
transcription 3 (acute-phase response 
Stat3 factor) 1.09E-04 2.68 
Down-regulated genes 
Fold 
Gene Abbr Gene Name p value Change 
ABI family, member 3 (NESH) binding 
ABI3BP protein 0.000148 0.48 
ACTC1 actin alpha cardiac muscle 1 3.41 E-05 0.24 
APLP2 amyloid beta (A4) precursor-like protein 2 1.17E-03 0.53 
calcium channel, voltage-dependent, L 
CACNA1S type, alpha 1 S subunit 0.002 0.63 
CBY1 chibby homolog 1 (Drosophila) 6.71 E-04 0.54 
COL2A1 collagen, type II, alpha 1 1.80E-03 0.65 
COL3A1 collagen, type Ill, alpha 1 1.90E-03 0.45 
COL5A1 collagen, type V, alpha 1 6.65E-04 0.53 
COL5A2 collagen, type V, alpha 2 7.60E-03 0.63 
COL5A3 collagen, type V, alpha 1 6.30E-04 0.57 
COL 11A1 collagen, type XI, alpha 1 1.72E-04 0.58 
DOK7 docking protein 7 8.01 E-05 0.55 
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EGF-Iike, fibronectin type Ill and laminin G 
EGFLAM domains 4.10E-03 0.66 
EGLN1 egl-9 family h_ypoxia-inducible factor 1 0.001 0.62 
HOMER1 homer homolog 1 (Drosophila) 3.04E-04 0.52 
HOXD10 homeobox D 1 0 0.0029 0.63 
HSPG2 heparan sulfate proteoglycan 2 6.43E-04 0.56 
Kazal-type serine peptidase inhibitor 
KAZALD1 domain 1 2.88E-03 0.62 
KY kyphoscoliosis peptidase 5.91E-06 0.09 
MEF2C myocyte enhancer factor 2C 2.38E-05 0.28 
myosin light chain, phosphorylatable, fast 
MYLPF skeletal muscle 1.83E-06 0.62 
MYOD1 myogenic differentiation 1 0.001 0.35 
P4HA1 prolyl 4-hydroxylase, alpha polypeptide I 0.00134 0.6 
p21 protein (Cdc42/Rac)-activated kinase 
PAK1 1 2.70E-04 0.35 
RARB retinoic acid receptor, beta 0.0047 0.45 
RBP4 retinol binding protein 4, plasma 5.54E-04 0.54 
RXRG retinoid X receptor,_gamma 1.60E-04 0.36 
serpin peptidase inhibitor, clade H (heat 
shock protein 47) , member 1, (collagen 
SERPINH1 binding protein 1) 0.0037 0.58 
TGFB2 transforming growth factor, beta 2 5.54E-05 0.43 
TNC tenascin C 0.0069 0.53 
Table 53. Fold changes for the cachex1a-mduced up- and down-regulated 
genes (at least 2::1 .5-fold). Fold changes for up-regulated genes match the 
genes shown in the heatmap (Figure 12). Fold changes for down-regulated 
genes are from a subset of the DAVID-identified GO categories shown in Table 
1. 
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Table 54. Genes with peaks from p65 ChiP-seq 
Control C26 Intersect Control Control C26 C26 
p65 p65 Array+ Array- Array+ Array-
Ankrdll Akrlc21 CAV2 CBLB HDHD3 FBX06 AR 
Bcl2111 Ano6 CD200 FKBPS IBTK RHOBTBl 
Bcorll Ar EZH2 FOSL2 ITGB6 
Camk2g Arhgap24 GM15319 HSF2 JPH2 
Cav2 Brd3 GM17267 MIDl NAV2 
Cblb Cav2 GM17379 STEAP4 
Cd200 Cd200 GM17467 
Cd244 Cwc27 GM17521 
Cdc27 Cytip GM4868 
Chrm2 Dcaf4 GM6604 
Cnga2 Dux GM773 
Col4a6 Ezh2 HEATR7B1 
Cxcl2 Fbxo6 HJURP 
Cythl Gm13212 HSF2 
Dst Gm15319 MEX3C 
Eepdl Gm17267 MIDl . 
Efcab9 Gm17379 OSBPL10 
EfnaS Gm17467 SLC7A15 
Ehd4 Gm17521 SP110 
Epasl Gm2964 SP140 
Ezh2 Gm4868 TRPM8 
FkbpS Gm595 UGT1A1 
Fosl2 Gm6604 VMN2R121 
Gm10719 Gm773 XLR 
Gm12824 Gm9867 ZFP36L3 
Gm15319 Heatr7b1 
Gm15319 Hjurp 
Gm15319 Hsf2 
Gm17267 lnppSa 
Gm17267 Kcnip4 
Gm17379 Lrch2 
Gm17467 Mex3c 
Gm17503 Midl 
Gm17521 Ncor2 
Gm4868 OsbpllO 
Gm6604 Pdzd2 
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Gm6604 Po me 
Gm6793 Puml 
Gm773 Rhobtbl 
Gna14 SemaSa 
Hdhd3 Slc7a15 
Heatr7bl SpllO 
Hjurp Sp140 
Hsf2 Srpk2 
lbtk Tada3 
lfi203 TnfsflS 
lft27 Trpm8 
lkbkb Ube2s 
ltgb6 Ugtlal 
ltlnl Ugt3al 
Jphl UsplS 
Jph2 Usp45 
Ken mal Vmn2r12 
1 
Kif26b Vmn2r75 
Klf8 Xlr 
Lcp2 Zfp3613 
Ligl Zmizl 
Lmbrdl 
Lpar3 
Mex3c 
Midl 
Mrpl32 
Nav2 
Olfm3 
OsbpllO 
Osbplla 
Osbpl9 
Pankl 
Pisd 
Rdh13 
Rnf128 
Rps26-ps1 
Scafll 
Scd3 
Sfil 
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Sfil 
Slc7a15 
SpllO 
Sp140 
Stagl 
Steap4 
Tmem39a 
Tnfaip8 
Trim33 
Trim52 
Trpm8 
Ubr4 
Ugtlal 
Usp32 
Vmnlr2 
Vmn2r121 
Vmn2r121 
Vmn2r121 
Vmn2r89 
Xlr 
Zfp3613 
Zfp512 
Zfp653 
Zfp692 
Zmat2 
Table 54. The genes with p65 ChiP-seq peaks from control {no tumor) and 
C26 muscle. From left to right the columns are: control p65, with reference to no 
antibody background alignments; C26 p65, with reference to no antibody 
background alignments; Intersect, the genes in common between control and 
C26; Control/Array+, the genes from Control ChiP-seq in common with >1.5 fold 
upregulated genes from the gene expression microarray; Control/Array-, the 
genes from the Control ChiP-seq in common with >1.5 fold downregulated genes 
from the gene expression microarray; C26/Array+, the genes from C26 ChiP-seq 
in common with >1 .5 fold upregulated genes from the gene expression 
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microarray; C26/Array-, the genes from the C26 ChiP-seq in common with >1.5 
fold downregulated genes from the gene expression microarray. 
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List of abbreviations 
C26 Colon 26 
ATG-5 autophagy related 5 
Bcl-3 B-cell CLL/Iymphoma 3 
BSA bovine serum albumin 
c control 
c. a. constitutively active 
C/EBP CCAAT/enhancer binding protein 
ChiP chromatin immunoprecipitation 
ChiP-seq chromatin immunoprecipitation-sequencing 
CM conditioned medium 
CSA cross sectional area 
CYLD cylindromatosis 
d.n. dominant negative 
DOKl docking protein 1 downstream of tyrosine kinase 1 
E glutamic acid 
EDL extensor digitorum longus 
EGFP enhanced green fluorescent protein 
ELISA enzyme-linked immunosorbent assay 
EMSA electrophoretic mobility shift assay 
EV empty vector 
FoxO forkhead box 0 
GP gastrocnemius/plantaris 
IFNy interferon gamma 
IKKa Inhibitor of kappa B kinase alpha 
IKKI3 Inhibitor of kappa B kinase beta 
IKKy Inhibitor of kappa B kinase gamma 
IL-l interleukin-1 
IL-6 interleukin-6 
IRS-1 insulin receptor substrate 1 
IKBa Inhibitor of kappa B alpha 
JCAl mouse prostate cancer cell line 
K lysine 
LLC Lewis lung carcinoma 
M methionine 
MAC 16 mouse adenocarcinoma 
MAFbx/Fbxo32/atroginl muscle atrophy F box protein/F-box protein 32 
muscle specific constitutively active IKK-expressing transgenic 
MIKK mouse 
MuRFl/Trim 63 muscle-specific RING finger protein/tri-partite motif containing 63 
127 
NBD NEMO binding domain 
NEMO NF-KB essential modulator 
NF-KB Nuclear factor of kappa B 
NIK NF-KB inducing kinase 
PCR polymerase chain reaction 
PIF proteolysis inducing factor 
RHD Rei homology domain 
s serine 
SNAP23 synaptosomal associated protein 23 
SOCS3 suppressor of cytokine signaling 
SR super repressor 
STAT3 signal transducer and activator of transcription 3 
TA tibialis anterior 
TAD transactivation domain 
TN Fa tumor necrosis factor alpha 
TSS transcription start site 
Ub ubiquitin 
YAH Yoshida ascites hepatoma 
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